coviduvlamp.com
Open in
urlscan Pro
192.185.23.100
Public Scan
Submitted URL: http://coviduvlamp.com/
Effective URL: https://coviduvlamp.com/
Submission: On September 18 via manual from GB
Effective URL: https://coviduvlamp.com/
Submission: On September 18 via manual from GB
Summary
This website contacted 7 IPs
in 3 countries
across 6 domains to perform 14 HTTP transactions.
The main IP is 192.185.23.100, located in
Houston, United States and
belongs to UNIFIEDLAYER-AS-1, US.
The main domain is coviduvlamp.com.
TLS certificate: Issued by Let's Encrypt Authority X3 on September 3rd 2020. Valid for: 3 months.
This is the only time coviduvlamp.com was scanned on urlscan.io!
TLS certificate: Issued by Let's Encrypt Authority X3 on September 3rd 2020. Valid for: 3 months.
This is the only time coviduvlamp.com was scanned on urlscan.io!
urlscan.io Verdict: No classification
Domain & IP information
| IP Address | AS Autonomous System | ||
|---|---|---|---|
| 1 2 | 192.185.23.100 192.185.23.100 | 46606 (UNIFIEDLA...) (UNIFIEDLAYER-AS-1) | |
| 1 | 2a00:1450:400... 2a00:1450:4001:803::200e | 15169 (GOOGLE) (GOOGLE) | |
| 3 | 2606:4700:303... 2606:4700:3032::681b:b58d | 13335 (CLOUDFLAR...) (CLOUDFLARENET) | |
| 4 | 2a00:1450:400... 2a00:1450:4001:81f::200a | 15169 (GOOGLE) (GOOGLE) | |
| 1 | 35.201.118.58 35.201.118.58 | 15169 (GOOGLE) (GOOGLE) | |
| 3 | 2a00:1450:400... 2a00:1450:4001:801::2003 | 15169 (GOOGLE) (GOOGLE) | |
| 14 | 7 |
2
192.185.23.100
(Houston, United States)
ASN46606 (UNIFIEDLAYER-AS-1, US)
PTR: 192-185-23-100.unifiedlayer.com
ASN46606 (UNIFIEDLAYER-AS-1, US)
PTR: 192-185-23-100.unifiedlayer.com
| coviduvlamp.com |
3
2606:4700:3032::681b:b58d
(United States)
ASN13335 (CLOUDFLARENET, US)
ASN13335 (CLOUDFLARENET, US)
| www.freevisitorcounters.com |
4
2a00:1450:4001:81f::200a
(Frankfurt am Main, Germany)
ASN15169 (GOOGLE, US)
ASN15169 (GOOGLE, US)
| translate.googleapis.com |
1
35.201.118.58
(Ascension Island)
ASN15169 (GOOGLE, US)
PTR: 58.118.201.35.bc.googleusercontent.com
ASN15169 (GOOGLE, US)
PTR: 58.118.201.35.bc.googleusercontent.com
| form.jotform.com |
| Apex Domain Subdomains |
Transfer | |
|---|---|---|
| 4 |
googleapis.com
translate.googleapis.com |
92 KB |
| 3 |
gstatic.com
www.gstatic.com |
4 KB |
| 3 |
freevisitorcounters.com
www.freevisitorcounters.com |
4 KB |
| 2 |
coviduvlamp.com
1 redirects
coviduvlamp.com |
52 KB |
| 1 |
jotform.com
form.jotform.com |
|
| 1 |
google.com
translate.google.com |
1 KB |
| 14 | 6 |
| Domain | Requested by | |
|---|---|---|
| 4 | translate.googleapis.com |
translate.google.com
translate.googleapis.com srcdoc |
| 3 | www.gstatic.com |
coviduvlamp.com
translate.googleapis.com |
| 3 | www.freevisitorcounters.com |
coviduvlamp.com
|
| 2 | coviduvlamp.com | 1 redirects |
| 1 | form.jotform.com |
coviduvlamp.com
|
| 1 | translate.google.com |
coviduvlamp.com
|
| 14 | 6 |
This site contains links to these domains. Also see Links.
| Subject Issuer | Validity | Valid | |
|---|---|---|---|
| webdisk.hospitaldisinfectants.net Let's Encrypt Authority X3 |
2020-09-03 - 2020-12-02 |
3 months | crt.sh |
| *.google.com GTS CA 1O1 |
2020-08-26 - 2020-11-18 |
3 months | crt.sh |
| sni.cloudflaressl.com Cloudflare Inc ECC CA-3 |
2020-08-05 - 2021-08-05 |
a year | crt.sh |
| upload.video.google.com GTS CA 1O1 |
2020-08-26 - 2020-11-18 |
3 months | crt.sh |
| *.jotform.com Sectigo RSA Domain Validation Secure Server CA |
2019-07-17 - 2021-07-16 |
2 years | crt.sh |
| *.gstatic.com GTS CA 1O1 |
2020-08-26 - 2020-11-18 |
3 months | crt.sh |
This page contains 3 frames:
Primary Page:
https://coviduvlamp.com/
Frame ID: C93D2AF7A58C4B1120C900B991F89E4E
Requests: 11 HTTP requests in this frame
Frame:
https://form.jotform.com/202475292012346
Frame ID: FF9AE7FE883169FC12A63E4E8268506D
Requests: 1 HTTP requests in this frame
Frame:
https://translate.googleapis.com/translate_a/l?client=te&alpha=true&hl=en&cb=callback
Frame ID: EC2816E11372F2C8F75A04F3BC063121
Requests: 1 HTTP requests in this frame
Screenshot
Page URL History Show full URLs
-
http://coviduvlamp.com/
HTTP 301
https://coviduvlamp.com/ Page URL
Detected technologies
Apache
(Web Servers)
Expand
Overall confidence: 100%
Detected patterns
Detected patterns
- headers server /(?:Apache(?:$|\/([\d.]+)|[^/-])|(?:^|\b)HTTPD)/i
Page Statistics
11 Outgoing links
These are links going to different origins than the main page.
URL: https://translate.google.com/
Title: Translate
Title: Translate
Search URL Search Domain Scan URL
URL: https://airdisinfectant.net/
Title: airdisinfectant.net
Title: airdisinfectant.net
Search URL Search Domain Scan URL
URL: https://hospitaldisinfectants.net/
Title: hospitaldisinfectants.net
Title: hospitaldisinfectants.net
Search URL Search Domain Scan URL
URL: https://medical-covid.com/
Title: medical-covid.com
Title: medical-covid.com
Search URL Search Domain Scan URL
URL: https://medical-covid.net/
Title: medical-covid.net
Title: medical-covid.net
Search URL Search Domain Scan URL
URL: https://www.symptoma.ro/
Title: symptoma
Title: symptoma
Search URL Search Domain Scan URL
URL: https://www.freevisitorcounters.com/en/home/stats/id/741796
Search URL Search Domain Scan URL
URL: https://youtube.com/
Title: medical serena medical tennis medical football medical baseball medical Messi medical Ronaldo medical Neymar medical Us coronavirus serena coronavirus tennis coronavirus football coronavirus baseball coronavirus Messi coronavirus Ronaldo coronavirus Neymar coronavirus Us facebook serena facebook tennis facebook football facebook baseball facebook Messi facebook Ronaldo facebook Neymar facebook Us google serena google tennis google football google baseball google Messi google Ronaldo google Neymar google Us xxx serena xxx tennis xxx football xxx baseball xxx Messi xxx Ronaldo xxx Neymar xxx Us how serena how tennis how football how baseball how Messi how Ronaldo how Neymar how Us to serena to tennis to football to baseball to Messi to Ronaldo to Neymar to Us do serena do tennis do football do baseball do Messi do Ronaldo do Neymar do Us medical netfilx coronavirus netfilx facebook netfilx google netfilx xxx netfilx how netfilx to netfilx do netfilx medical police coronavirus police facebook police google police xxx police how police to police do police medical stars coronavirus stars facebook stars google stars xxx stars how stars to stars do stars medical covid coronavirus covid facebook covid google covid xxx covid how covid to covid do covid medical healt coronavirus healt facebook healt google healt xxx healt how healt to healt do healtmedical domain coronavirus domain facebook domain google domain xxx domain how domain to domain do domain medical domain name coronavirus domain name facebook domain name google domain name xxx domain name how domain name to domain name do domain name medical domain names coronavirus domain names facebook domain names google domain names xxx domain names how domain names to domain names do domain names
Title: medical serena medical tennis medical football medical baseball medical Messi medical Ronaldo medical Neymar medical Us coronavirus serena coronavirus tennis coronavirus football coronavirus baseball coronavirus Messi coronavirus Ronaldo coronavirus Neymar coronavirus Us facebook serena facebook tennis facebook football facebook baseball facebook Messi facebook Ronaldo facebook Neymar facebook Us google serena google tennis google football google baseball google Messi google Ronaldo google Neymar google Us xxx serena xxx tennis xxx football xxx baseball xxx Messi xxx Ronaldo xxx Neymar xxx Us how serena how tennis how football how baseball how Messi how Ronaldo how Neymar how Us to serena to tennis to football to baseball to Messi to Ronaldo to Neymar to Us do serena do tennis do football do baseball do Messi do Ronaldo do Neymar do Us medical netfilx coronavirus netfilx facebook netfilx google netfilx xxx netfilx how netfilx to netfilx do netfilx medical police coronavirus police facebook police google police xxx police how police to police do police medical stars coronavirus stars facebook stars google stars xxx stars how stars to stars do stars medical covid coronavirus covid facebook covid google covid xxx covid how covid to covid do covid medical healt coronavirus healt facebook healt google healt xxx healt how healt to healt do healtmedical domain coronavirus domain facebook domain google domain xxx domain how domain to domain do domain medical domain name coronavirus domain name facebook domain name google domain name xxx domain name how domain name to domain name do domain name medical domain names coronavirus domain names facebook domain names google domain names xxx domain names how domain names to domain names do domain names
Search URL Search Domain Scan URL
URL: https://business.facebook.com/
Title: No Cause For 'concern' After Berlusconi Admitted To Hospital With Covid-19 Silvio Berlusconi wearing a suit and tie: Former Prime Minister Silvio Berlusconi speaks at a rally in Rome on October 2019. © Tiziana Fabi/AFP/Getty Images Former Prime Minister Silvio Berlusconi speaks at a rally in Rome on October 2019. There is no cause for "concern" over the health of former Italian Prime Minister Silvio Berlusconi after he was admitted to hospital with coronavirus, his representatives told CNN. The 83-year-old media magnate, who first became the country's leader in 1994, was admitted to hospital on Thursday with mild coronavirus symptoms. He subsequently tested positive for Covid-19. "Berlusconi, after the appearance of some symptoms, was admitted to the San Raffale hospital in Milan as a precaution. The clinical picture does not cause concern," his press office told CNN. It comes after his press office told CNN Wednesday that the former Italian Prime Minister had coronavirus but was not displaying symptoms. "He did a precautionary swab test but was asymptomatic. He is currently in his Arcore home [near Milan, in the Italian region of Lombardy] where he will continue to work and give interviews remotely," his representatives said Wednesday. Italy reported 996 new Covid-19 cases and six deaths on Monday, with the region of Campania recording 184 infections. This marked the first time a southern region had seen the highest daily rate of cases. As of Monday, there were 94 coronavirus patients being treated in Italian Intensive Care Units across the country, more than at any date since June 29. Italy has so far recorded 35,507 deaths from coronavirus and more than 272,000 confirmed cases, according to Johns Hopkins University. Italy was one of the earliest European countries to see a spike in coronavirus cases, and strict lockdown measures were introduced in March. Parts of society have reopened, and summer has been in full swing in the country. But despite the success story in beating back the virus, Italy has suffered tremendous economic losses, with GDP expected to contract by around 10% this year. Tyra Banks: Len Goodman May Not Return To ‘DWTS’ Ballroom Due To COVID-19 Travel Restrictions Are more changes coming to Dancing With the Stars? In a new interview, host Tyra Banks hinted that judge Len Goodman may not be part of the upcoming 29th season. “Carrie Ann [Inaba] is definitely back, and Bruno [Tonioli], who I can’t wait to vibe with because he is just as crazy as I am,†Banks, 46, told Entertainment Tonight in an interview posted on Friday, September 4. “At the moment, we’re trying to figure out how to incorporate Len Goodman because he is in England, and there’s all these travel restrictions because of COVID-19. So we’re trying to figure that out.†Len Goodman May Not Return to DWTSLen Goodman on “Dancing with the Stars: Athletes.†ABC Goodman, 76, has been part of the ABC reality show since 2005. He left the show in season 21 but returned the following season. A source confirmed with Us Weekly that the network is working to find a way to keep the London native as a part of the show. Of course, that would be only one of the many changes coming this season, as hosts Tom Bergeron and Erin Andrews were ousted from the show and replaced by the America’s Next Top Model creator. Additionally, many new protocols have been put in place in order to prevent the spread of coronavirus — including married pros not being able to live together during the season. For Banks, her biggest challenge is “stepping into two shoes,†she told Us exclusively on Thursday, September 3. Tyra Banks Len Goodman May Not Return to DWTSTyra Banks at theAmerican Influencer Awards. Shutterstock “Tom Bergeron and Erin, they lead the show. This is one of the top-rated shows in the world. So me, respecting the stage that they have set and then adding my icing to that [is a challenge],†she said. “I feel confident about that, but of course, it’s a challenge. I don’t back away from challenges.†Derek Hough is also being added to this season “in a very interesting way,†the supermodel told ET. The professional dancer, 35, competed on the show from 2006 to 2017, winning season 7, season 10, season 11, season 16, season 17 and season 21. “I am very excited about that because I know Derek and he’s fun,†the Modelland author teased. “But you just gonna have to wait and see how he’s coming back.†Hough’s role will be revealed during Good Morning America on Tuesday, September 8. Dancing With the Stars premieres on ABC Monday, September 14, at 8 p.M. ET. Listen to Watch With Us to hear more about your favorite shows and for the latest TV news! Dozens Of U.S. Hospitals May Defy FDA’s Directive On COVID Plasma BEN STANSALL/AFP via Getty Dozens of major hospitals across the U.S. Are grappling with whether to ignore a federal decision allowing broader emergency use of blood plasma from recovered COVID patients to treat the disease in favor of dedicating their resources to a gold-standard clinical trial that could help settle the science for good. As many as 45 hospitals from coast to coast have expressed interest in collaborating on a randomized, controlled clinical trial sponsored by Vanderbilt University Medical Center, said principal investigator Dr. Todd Rice. Officials at some hospitals said they are considering committing only to the clinical trial — and either avoiding or minimizing use of convalescent plasma through an emergency use authorization issued Aug. 23 by the federal Food and Drug Administration. The response comes amid concerns that the Trump administration pressured the FDA into approving broader use of convalescent plasma, which already has been administered to more than 77,000 COVID patients in the U.S. President Donald Trump characterized the treatment as a “powerful therapy,†even as government scientists called for more evidence that COVID plasma is beneficial. A National Institutes of Health panel this week countered the FDA’s decision, saying that the therapy “should not be considered the standard of care for the treatment of patients with COVID-19†and that well-designed trials are needed to determine whether the therapy is helpful. Data so far suggests the treatment could be beneficial, but it’s not definitive. “It’s an important scientific question that we don’t have the answer to yet,†said Rice, an associate professor of medicine and director of VUMC’s medical intensive care unit. Convalescent plasma uses an antibody-rich blood product taken from people who have recovered from a viral infection and injects it into people still suffering in the hopes that the therapy will jump-start their immune systems, boosting their ability to fight the virus. The approach has been used on an experimental basis for more than a century to fight other virulent diseases, including the 1918 flu, measles, Ebola, SARS and H1N1 influenza. Story continues Last month, NIH officials awarded $34 million to Rice’s study, the Passive Immunity Trial of the Nation for COVID-19, dubbed PassItOnII, which has also received funding from country music superstar Dolly Parton. The trial, which aims to enroll 1,000 adult hospitalized patients, could meet its goals by the end of October. If it shows evidence of likely benefit to COVID patients, it could immediately change clinical practice, Rice said. RELATED: No Sign that Plasma from Recovered Patients Is an Effective Coronavirus Treatment, Panel Says Half of the participants will receive convalescent plasma with high levels of disease-fighting antibodies from a stockpile of more than 150 units of the product already collected, Rice said. The other half will receive a placebo solution. Though the trial launched in April, enrollment has been slow. The funding allows enlistment at more than 50 sites nationwide. That has spurred new conversations about joining the trial — and about not employing the controversial authorization issued by the FDA, said Dr. Claudia Cohn, director of the Blood Bank Laboratory at the University of Minnesota Medical School. She expected her institution to decide this week. “I’d rather frame it as not rejecting the FDA, but simply taking the longer view,†said Cohn, who is also medical director for the AABB, an international nonprofit focused on transfusion medicine and cellular therapies. RELATED: Trump Announces Emergency Authorization for COVID-19 Plasma Treatment After Attacking FDA At the Ohio State University Wexner Medical Center, officials have opted to join the trial and are considering making it “the first option†for COVID patients who qualify, said Dr. Sonal Pannu, an assistant professor and pulmonologist. “Many of the academic leaders believe we should do the trial, and we would be severely limiting†the emergency use authorization, or EUA, she said, noting that first patients could be enrolled soon. The plasma still could be used under the EUA to treat patients such as prisoners, who are unable to consent to join a clinical trial, she added. That’s the same stance adopted by the University of Washington, said Dr. Nicholas Johnson, an assistant professor of emergency medicine who’s leading the trial at the Seattle site. “We’re really interested in enrolling patients as the first option,†he said. The questions are similar to those raised with hydroxychloroquine, another treatment Trump touted for treating COVID-19. FDA officials issued an EUA for the drug in April, only to revoke it in June after data indicated the drug might be harmful. “On a couple of occasions, we’ve allowed clinical practice to get ahead of the science,†Johnson said. “We’ve learned that lesson a couple of times now.†FDA officials did not respond to requests for comment. Top federal health leaders, including NIH Director Dr. Francis Collins and Dr. Anthony Fauci, the nation’s leading infectious disease doctor, initially resisted the move to issue the EUA for convalescent plasma last month, telling The New York Times that the evidence for it was too weak. Trump has criticized the FDA for moving too slowly to speed approval of treatments and vaccines for COVID-19. He announced the EUA on the eve of the Republican National Convention, calling it a “truly historic announcement.†Issuing the EUA puts the fate of clinical trials into “extreme jeopardy,†said Arthur Caplan, a professor of bioethics at the New York University School of Medicine. With convalescent plasma in very short supply, it sets the stage for fights over access and makes sick patients less inclined to join a trial, where they might receive a placebo. “If you have the EUA, it starts to damage the trials,†Caplan said. Still, given that the FDA has authorized convalescent plasma for patients ill with COVID-19, hospitals that hesitate or refuse to provide it outside a trial are sure to face questions from families. That creates “a very interesting and delicate ethics problem,†said Cohn. “If you commit to the randomized controlled trial only, you’re committing to a long-term dedication to science,†she said. “The question is, is it ethically inappropriate not to provide a therapy that has been shown to be possibly beneficial?†Johnson, at the University of Washington, said most patients have been willing — even eager — to participate in clinical trials once they understand the need for rigorous scientific results. And Caplan, the bioethicist, applauded the decision of hospitals to minimize the EUA and focus on the trial, calling it “a pretty feisty action.†“It’s sensible,†he said. “It’s likely to really generate an answer to the question of ‘Does COVID convalescent plasma do anything?’†Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.
Title: No Cause For 'concern' After Berlusconi Admitted To Hospital With Covid-19 Silvio Berlusconi wearing a suit and tie: Former Prime Minister Silvio Berlusconi speaks at a rally in Rome on October 2019. © Tiziana Fabi/AFP/Getty Images Former Prime Minister Silvio Berlusconi speaks at a rally in Rome on October 2019. There is no cause for "concern" over the health of former Italian Prime Minister Silvio Berlusconi after he was admitted to hospital with coronavirus, his representatives told CNN. The 83-year-old media magnate, who first became the country's leader in 1994, was admitted to hospital on Thursday with mild coronavirus symptoms. He subsequently tested positive for Covid-19. "Berlusconi, after the appearance of some symptoms, was admitted to the San Raffale hospital in Milan as a precaution. The clinical picture does not cause concern," his press office told CNN. It comes after his press office told CNN Wednesday that the former Italian Prime Minister had coronavirus but was not displaying symptoms. "He did a precautionary swab test but was asymptomatic. He is currently in his Arcore home [near Milan, in the Italian region of Lombardy] where he will continue to work and give interviews remotely," his representatives said Wednesday. Italy reported 996 new Covid-19 cases and six deaths on Monday, with the region of Campania recording 184 infections. This marked the first time a southern region had seen the highest daily rate of cases. As of Monday, there were 94 coronavirus patients being treated in Italian Intensive Care Units across the country, more than at any date since June 29. Italy has so far recorded 35,507 deaths from coronavirus and more than 272,000 confirmed cases, according to Johns Hopkins University. Italy was one of the earliest European countries to see a spike in coronavirus cases, and strict lockdown measures were introduced in March. Parts of society have reopened, and summer has been in full swing in the country. But despite the success story in beating back the virus, Italy has suffered tremendous economic losses, with GDP expected to contract by around 10% this year. Tyra Banks: Len Goodman May Not Return To ‘DWTS’ Ballroom Due To COVID-19 Travel Restrictions Are more changes coming to Dancing With the Stars? In a new interview, host Tyra Banks hinted that judge Len Goodman may not be part of the upcoming 29th season. “Carrie Ann [Inaba] is definitely back, and Bruno [Tonioli], who I can’t wait to vibe with because he is just as crazy as I am,†Banks, 46, told Entertainment Tonight in an interview posted on Friday, September 4. “At the moment, we’re trying to figure out how to incorporate Len Goodman because he is in England, and there’s all these travel restrictions because of COVID-19. So we’re trying to figure that out.†Len Goodman May Not Return to DWTSLen Goodman on “Dancing with the Stars: Athletes.†ABC Goodman, 76, has been part of the ABC reality show since 2005. He left the show in season 21 but returned the following season. A source confirmed with Us Weekly that the network is working to find a way to keep the London native as a part of the show. Of course, that would be only one of the many changes coming this season, as hosts Tom Bergeron and Erin Andrews were ousted from the show and replaced by the America’s Next Top Model creator. Additionally, many new protocols have been put in place in order to prevent the spread of coronavirus — including married pros not being able to live together during the season. For Banks, her biggest challenge is “stepping into two shoes,†she told Us exclusively on Thursday, September 3. Tyra Banks Len Goodman May Not Return to DWTSTyra Banks at theAmerican Influencer Awards. Shutterstock “Tom Bergeron and Erin, they lead the show. This is one of the top-rated shows in the world. So me, respecting the stage that they have set and then adding my icing to that [is a challenge],†she said. “I feel confident about that, but of course, it’s a challenge. I don’t back away from challenges.†Derek Hough is also being added to this season “in a very interesting way,†the supermodel told ET. The professional dancer, 35, competed on the show from 2006 to 2017, winning season 7, season 10, season 11, season 16, season 17 and season 21. “I am very excited about that because I know Derek and he’s fun,†the Modelland author teased. “But you just gonna have to wait and see how he’s coming back.†Hough’s role will be revealed during Good Morning America on Tuesday, September 8. Dancing With the Stars premieres on ABC Monday, September 14, at 8 p.M. ET. Listen to Watch With Us to hear more about your favorite shows and for the latest TV news! Dozens Of U.S. Hospitals May Defy FDA’s Directive On COVID Plasma BEN STANSALL/AFP via Getty Dozens of major hospitals across the U.S. Are grappling with whether to ignore a federal decision allowing broader emergency use of blood plasma from recovered COVID patients to treat the disease in favor of dedicating their resources to a gold-standard clinical trial that could help settle the science for good. As many as 45 hospitals from coast to coast have expressed interest in collaborating on a randomized, controlled clinical trial sponsored by Vanderbilt University Medical Center, said principal investigator Dr. Todd Rice. Officials at some hospitals said they are considering committing only to the clinical trial — and either avoiding or minimizing use of convalescent plasma through an emergency use authorization issued Aug. 23 by the federal Food and Drug Administration. The response comes amid concerns that the Trump administration pressured the FDA into approving broader use of convalescent plasma, which already has been administered to more than 77,000 COVID patients in the U.S. President Donald Trump characterized the treatment as a “powerful therapy,†even as government scientists called for more evidence that COVID plasma is beneficial. A National Institutes of Health panel this week countered the FDA’s decision, saying that the therapy “should not be considered the standard of care for the treatment of patients with COVID-19†and that well-designed trials are needed to determine whether the therapy is helpful. Data so far suggests the treatment could be beneficial, but it’s not definitive. “It’s an important scientific question that we don’t have the answer to yet,†said Rice, an associate professor of medicine and director of VUMC’s medical intensive care unit. Convalescent plasma uses an antibody-rich blood product taken from people who have recovered from a viral infection and injects it into people still suffering in the hopes that the therapy will jump-start their immune systems, boosting their ability to fight the virus. The approach has been used on an experimental basis for more than a century to fight other virulent diseases, including the 1918 flu, measles, Ebola, SARS and H1N1 influenza. Story continues Last month, NIH officials awarded $34 million to Rice’s study, the Passive Immunity Trial of the Nation for COVID-19, dubbed PassItOnII, which has also received funding from country music superstar Dolly Parton. The trial, which aims to enroll 1,000 adult hospitalized patients, could meet its goals by the end of October. If it shows evidence of likely benefit to COVID patients, it could immediately change clinical practice, Rice said. RELATED: No Sign that Plasma from Recovered Patients Is an Effective Coronavirus Treatment, Panel Says Half of the participants will receive convalescent plasma with high levels of disease-fighting antibodies from a stockpile of more than 150 units of the product already collected, Rice said. The other half will receive a placebo solution. Though the trial launched in April, enrollment has been slow. The funding allows enlistment at more than 50 sites nationwide. That has spurred new conversations about joining the trial — and about not employing the controversial authorization issued by the FDA, said Dr. Claudia Cohn, director of the Blood Bank Laboratory at the University of Minnesota Medical School. She expected her institution to decide this week. “I’d rather frame it as not rejecting the FDA, but simply taking the longer view,†said Cohn, who is also medical director for the AABB, an international nonprofit focused on transfusion medicine and cellular therapies. RELATED: Trump Announces Emergency Authorization for COVID-19 Plasma Treatment After Attacking FDA At the Ohio State University Wexner Medical Center, officials have opted to join the trial and are considering making it “the first option†for COVID patients who qualify, said Dr. Sonal Pannu, an assistant professor and pulmonologist. “Many of the academic leaders believe we should do the trial, and we would be severely limiting†the emergency use authorization, or EUA, she said, noting that first patients could be enrolled soon. The plasma still could be used under the EUA to treat patients such as prisoners, who are unable to consent to join a clinical trial, she added. That’s the same stance adopted by the University of Washington, said Dr. Nicholas Johnson, an assistant professor of emergency medicine who’s leading the trial at the Seattle site. “We’re really interested in enrolling patients as the first option,†he said. The questions are similar to those raised with hydroxychloroquine, another treatment Trump touted for treating COVID-19. FDA officials issued an EUA for the drug in April, only to revoke it in June after data indicated the drug might be harmful. “On a couple of occasions, we’ve allowed clinical practice to get ahead of the science,†Johnson said. “We’ve learned that lesson a couple of times now.†FDA officials did not respond to requests for comment. Top federal health leaders, including NIH Director Dr. Francis Collins and Dr. Anthony Fauci, the nation’s leading infectious disease doctor, initially resisted the move to issue the EUA for convalescent plasma last month, telling The New York Times that the evidence for it was too weak. Trump has criticized the FDA for moving too slowly to speed approval of treatments and vaccines for COVID-19. He announced the EUA on the eve of the Republican National Convention, calling it a “truly historic announcement.†Issuing the EUA puts the fate of clinical trials into “extreme jeopardy,†said Arthur Caplan, a professor of bioethics at the New York University School of Medicine. With convalescent plasma in very short supply, it sets the stage for fights over access and makes sick patients less inclined to join a trial, where they might receive a placebo. “If you have the EUA, it starts to damage the trials,†Caplan said. Still, given that the FDA has authorized convalescent plasma for patients ill with COVID-19, hospitals that hesitate or refuse to provide it outside a trial are sure to face questions from families. That creates “a very interesting and delicate ethics problem,†said Cohn. “If you commit to the randomized controlled trial only, you’re committing to a long-term dedication to science,†she said. “The question is, is it ethically inappropriate not to provide a therapy that has been shown to be possibly beneficial?†Johnson, at the University of Washington, said most patients have been willing — even eager — to participate in clinical trials once they understand the need for rigorous scientific results. And Caplan, the bioethicist, applauded the decision of hospitals to minimize the EUA and focus on the trial, calling it “a pretty feisty action.†“It’s sensible,†he said. “It’s likely to really generate an answer to the question of ‘Does COVID convalescent plasma do anything?’†Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.
Search URL Search Domain Scan URL
URL: https://oms.gov/
Title: Kai Havertz To Undergo Chelsea Medical Ahead Of €80m Move Did Werner heighten expectations at Chelsea with goal vs. Spain? (1:29) Steve Nicol and Ale Moreno react to Timo Werner's superb goal in Germany's 1-1 draw with Spain. (1:29) Kai Havertz will undergo a medical on Friday, with Chelsea on the verge of completing a deal for the Bayer Leverkusen midfielder worth €80 million plus €20m in add-ons. The 21-year-old was given permission on Friday to leave the Germany national team training camp and fly to London to put the finishing touches to his deal. - Stream FC Daily on ESPN+- Insider Notebook: Man Utd boss Solskjaer vows to undo Sanchez mess Germany head coach Joachim Low confirmed he would not return for the side's Nations League match against Switzerland on Sunday, making him available for Chelsea's opening Premier League fixture on Sept. 14. • Messi makes Barca U-turn, says he'll stay• Messi's father denies €700m release clause• Havertz to undergo Chelsea medical• Sources: Sancho to Utd held up by fees• Sources: Barca's Suarez set for Juve move• Sanchez wanted to 'rip up' Utd contract• Moneyball guru buys stake in Dutch club• USMNT boss: Pulisic can play for Barca, Real "If he were to travel to Switzerland and return, I believe, he'd have to go into quarantine and the player, of course, wants a good start at Chelsea and this would be a disadvantage for him," Low said. The medical is not expected to raise any issues and the Blues are set to confirm Havertz as a Chelsea player by the end of the week, taking their summer spending spree past £200m with the acquisitions of Hakim Ziyech, Timo Werner and Ben Chilwell in addition to free signings Thiago Silva and Malang Sarr. Havertz was an unused substitute in Germany's 1-1 draw against Spain on Thursday evening. The decision not to play him was taken following consultation with Chelsea to avoid any risk of injury complicating his medical. This Medical Worker Used To Be A 'hero.' Now He Feels Hated That was five or six months ago, or perhaps another lifetime. When I talked to Parsia Jahanbani in mid-August, the warmth and goodwill were gone. Parsia works at Families Together of Orange County, a non-profit that provides medical and dental care to the underprivileged. He's an expanded-function dental assistant -- basically a dental nurse practitioner -- and he drives a giant bus called a mobile medical unit to various homeless shelters. His organization lost about one-third of its staff early in the pandemic to furloughs, resignations and other factors. The pandemic makes dental work especially dangerous. One morning, as colleagues departed, Parsia saw his 80-year-old father, the dental director, sitting behind his desk. "And I go to talk to him, 'I'm like, 'Why aren't you going home?' He's like, 'This is my ship. I'm the captain...I can't go home.' Like, 'You're 80. You're at risk. You -- if you get sick, this is it. Do you understand that?' And he starts crying." His father reluctantly went home, leaving Parsia to face his own dilemma at age 36. He has a rare and mysterious neurological condition called cluster headaches. These sporadic headaches come with seizures, and they've put him in the hospital several times. His treatment for the intermittent symptoms include immunosuppressive drugs that could increase his vulnerability to the coronavirus. More than 30 million Americans have lost their jobs this year. Millions more, including Parsia, have been forced to answer a horrifying question: Do I want or need my job so much that I'll keep doing it even if it might kill me? Parsia Jahanbani giving a coronavirus test. Parsia Jahanbani giving a coronavirus test. Parsia Jahanbani giving a coronavirus test. Parsia could recall a moment from a few years earlier, when his seizures were incapacitating. He says he made a deal with God: "Give me the health to do this and I promise to serve." And so, when the coronavirus question posed itself, Parsia answered yes. Now he wouldn't just do dental work. He'd be the one giving coronavirus tests. Sweating in his face shield and goggles and mask and full-body Tyvek suit, jamming swabs into the throats of strangers who coughed and sneezed all over him. "We knew that we were risking our lives going back to work," he said. "But I remember one day we showed up to the Salvation Army's emergency shelter and a group of our patients that are homeless, they were on a lockdown. They couldn't leave the shelter...And as I'm pulling up in the parking lot, I see five or six people standing behind the chain-link fence. And one of them was holding a pizza box. As we get closer, he kind of opens the lid of the pizza box. And on the top part of it, on the lid part of it, he had written, 'Thank you.' And the bottom part was, 'Our medical workers.' And he opened the box and kind of showed me the sign and the other four kind of clapped for us. And as I'm driving, I started crying. I started bawling. I couldn't hold it back. And I turned around and told the doctor, you know, 'This is why we're here.'" April, May, June. President Donald Trump encouraged armed protesters to rebel against mandatory shutdowns in Michigan. George Floyd was killed in Minneapolis. More than 1,000 health professionals signed a letter supporting the mass demonstrations that followed, leaving some Americans confused about which gatherings were safe. The coronavirus death toll surpassed 50,000; 100,000, 150,000. Across the political spectrum, people were some combination of sad, angry, tired, bored, sick of this whole nightmare of a decade of a year. National unity? A distant memory. Parsia kept working, although no one called him a hero anymore. Among the patients who had to get tested for work, some called the pandemic a hoax. One called Parsia a communist. "He pulled up with his car through the drive-through testing," Parsia told me. "I'm like, 'You are in the testing facility. You came to me. I didn't, like, force you to come get tested. And moreover, I -- if you don't believe in the virus and everything, then why are you getting tested?...You need to wear a mask. You need to follow the instructions.' The moment that we go to pull the swab to his face, here we go again. 'What the f**k are you doing?...Is there something on the swab? Where are you getting the swabs from? Go grab a new one. Open it in front of me. Want to make sure that you're not putting anything in my body.'" Some of the anger was justified. Test kits piled up at the lab. Some patients waited a month for results, which meant the tests were useless. If they were sick, they'd been spreading it for weeks by the time they knew. Parsia was exhausted, dehydrated, sweating in the suit for 12 hours a day. One day in August he collapsed and had to go to the hospital. Back at home, he lay awake in bed with his mind racing. He worried about infecting his wife, her parents. He thought about dying. He wrote out his will. And as he summoned the resolve to put on the Tyvek suit, Parsia thought of his father, Safaeddin Jahanbani. The captain of the ship. He'd been told to go home for his own safety at the start of the pandemic. Here's what happened next. "Every morning he would get up, shower, shave, put on his tie, and just sit by the dining table waiting for a call for him to go back to work," Parsia told me. "He wanted so bad to be a part of this and help in some way...He stayed home less than a month. Towards the end of it, he was telling me, like, 'If I don't work for much longer, you know, then I'm gonna die.' Right. Like, 'No, you're not, Dad. Come on.' Like, 'No, it's this, having a purpose in life that's keeping me going.' And I understood that. 'Cause even at 36, I feel the same...He says that's the oath that he took as a doctor, to serve, to protect. To be there for patients. Because he's like, 'Till my last breath, I'm going to be there. I'm going to see patients. I'm going to help people.'" And so they both went to work. I spoke with the father, Dr. Jahanbani, and he confirmed what his son told me. The signs didn't matter to him. Only the mission did. "This is not something to boast about, or to feel heroic," he said. "We do it very humbly." He said other workers deserved appreciation: airline pilots, cashiers in grocery stores, anyone clearing tables in restaurants. And he's right. I think of them often. All these people risking everything on a Monday morning or a Thursday night. Firefighters and meatpacking workers. Janitors, bus drivers, schoolteachers. A courageous multitude in a fracturing nation, holding us all together. Medical Marijuana, Inc. Announces Production And Warehouse Facility Expansion; Adds State-of-the-Art Manufacturing Capability And Hemp License TipRanks Billionaire Ken Griffin Snaps Up These 3 “Strong Buy†Stocks As fears of a tech bubble and stretched valuations become the talk of the town, investors are turning to Wall Street titans for guidance, namely Ken Griffin. Founding hedge fund Citadel in 1990, the firm now boasts over $35 billion worth of assets under management.As a 19-year-old sophomore at Harvard University, Griffin began trading from his dorm room with a fax machine, computer and phone. Now, the CEO of Citadel, whose net worth stands at $15.5 billion, is known as one of the Wall Street greats. Looking at the fund’s performance during the COVID crisis, it’s even more clear why Griffin has legendary status.Unlike the average hedge fund, which had a negative return of between 3-4% in the first half of 2020, Citadel’s flagship Wellington fund saw its returns land between 13-14% for the same period.Bearing this in mind, we wanted to take a closer look at three stocks Citadel snapped up recently. Using TipRanks’ database, we found out that each ticker has earned a “Strong Buy†consensus rating from the analyst community. Not to mention all three of them boast massive upside potential.AVEO Pharmaceuticals (AVEO)Hoping to provide better outcomes for patients, AVEO Pharmaceuticals advances targeted medicines for oncology and other unmet medical needs. Following an important regulatory milestone, it’s no wonder all eyes are on this healthcare name.Griffin is among those singing AVEO’s praises. Increasing its holding by a whopping 2,357%, Citadel bought up 383,720 shares in Q2. With the total position now landing at 400,003 shares, it is valued at $1,824,013.H.C. Wainwright analyst Swayampakula Ramakanth reminds investors that on June 1, the FDA accepted the NDA for tivozanib, the company's lead candidate, for review, based on the fact that the TIVO-3 study reported positive final overall survival (OS) data. In the study, AVEO’s therapy was compared to sorafenib, marketed as Nexavar by Bayer, for the treatment of advanced renal cell carcinoma (RCC) in the third and fourth-line settings.Looking more closely at the data, which was presented at the ASCO 2020 virtual meeting, the final OS analysis resulted in an overall hazard ratio (HR) of 0.97, which favored tivozanib. Ramakanth was “encouraged†by the OS results as they “suggest tivozanib at least has a similar overall relative risk of deaths compared to sorafenib.â€â€œConsidering that TIVO-3 study met both the primary endpoint of progression free survival (PFS) and the secondary endpoint of overall response rate (ORR), with comparable OS to the active comparator, we believe tivozanib would likely get a green light for the U.S. Approval, which could be a major catalyst in the next 12 months,†Ramakanth opined.Adding to the good news, the dose escalation for the Phase 1b/2 DEDUCTIVE study, evaluating tivozanib in combination with durvalumab, a monoclonal antibody against PD-L1 marketed as Imfinzi by AstraZeneca in hepatocellular carcinoma (HCC), has been wrapped up, with it progressing to Phase 2. As the CDC estimates about 33,000 patients suffer from liver cancer every year in the U.S., Ramakanth sees an additional opportunity.To this end, Ramakanth rates AVEO a Buy rating along with a $12 price target. Should his thesis play out, a potential twelve-month gain of 163% could be in the cards. (To watch Ramakanth’s track record, click here)Other analysts don’t beg to differ. 3 Buy ratings and no Holds or Sells have been assigned in the last three months. So, the word on the Street is that AVEO is a Strong Buy. The $15 average price target is more aggressive than Ramakanth’s and implies 229% upside potential. (See AVEO stock analysis on TipRanks)IDEAYA Biosciences (IDYA)Next up we have IDEAYA Biosciences, an oncology-focused precision medicine company that develops targeted therapeutics by using molecular diagnostics. Based on the strength of its technology, this name has scored several fans.Reflecting a new position for Griffin's Citadel, the fund pulled the trigger on 248,005 shares in Q2. As for the value of this holding, it comes in at $2,881,818. Writing for Northland Capital, analyst Tim Chiang believes shares are “undervalued based on the future potential of its precision medicine oncology pipeline, which targets specific biomarkers.†Expounding on this, he stated, “IDEAYA is applying its capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets.â€Part of what makes IDYA a stand-out, in Chiang’s opinion, is the fact that its preclinical programs use its synthetic lethality (SL) platform, which targets tumors with MTAP gene deletion and homologous recombination deficiency (HRD) including BRCA mutations.“We believe the longer-term upside potential with IDYA shares is significant given the potential utility of SL. The first clinically validated SL gene pair was PARP-BRCA1/2, and based on the efficacy of PARP inhibitors, the SL approach to treating cancer has achieved substantial commercial validation,†the analyst explained.To back this up, Chiang points out that several PARP inhibitors have already been approved for the treatment of tumors with BRCA and other DNA damage repair alterations, including ovarian, breast and pancreatic cancers. These inhibitors include AstraZeneca's olaparib, GlaxoSmithKline's niraparib, Pfizer's talazoparib and Clovis’ rucaparib. He added, “We estimate these four drugs generated over $1.6 billion in worldwide sales in 2019 and are expected to reach over $6 billion in sales by 2024.â€It should be noted that multiple IND filings are set to come within the next 4-12 months, with IDYA’s lead SL candidate, IDE397, which was designed to inhibit MTAP and MAT2A and thus cause the death of cancerous tumor cells, entering the clinic in 2021.It should come as no surprise, then, that Chiang joined the bulls. To start off his IDYA coverage, he puts an Outperform rating and $28 price target on the stock. This target implies a possible twelve-month rise of 141% could be on the horizon. (To watch Chiang’s track record, click here)Similarly, the rest of the Street is getting onboard. 5 Buy ratings assigned in the last three months add up to a Strong Buy analyst consensus. In addition, the $25.20 average price target puts the potential twelve-month gain at 116%. (See IDYA stock analysis on TipRanks)Ocular Therapeutix (OCUL)Using its patented bioresorbable hydrogel-based formulation technology, Ocular Therapeutix develops cutting-edge therapies for diseases and conditions of the eye. The progress of its clinical programs has caught Wall Street’s attention, with some arguing that now is the time to get in on the action.Griffin and Citadel didn’t want to miss out on an opportunity. Snapping up 161,032 shares during Q2, the hedge fund gave the holding a 272% boost. The total position is now comprised of 220,269 shares and is valued at $1,718,098.Representing Raymond James, 5-star analyst Dane Leone cites the potential to address the unmet needs in the dry eye disease indication as a key component of his bullish thesis. The company boasts two assets targeting the condition, OTX-CSI (chronic) and OTX-DED (acute). OTX-CSI incorporates the FDA-approved immunomodulator cyclosporine as the active drug in the intracanalicular insert, which is released for an estimated three months to increase tear production.When it comes to OTX-DED, Leone argues OCUL was “clever in pursuing the development of OTX-DED (a low dose form of DEXTENZA, a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus to deliver dexamethasone to the ocular surface for up to 30 days without preservatives) for the treatment of episodic dry eye, as the prior safety data from the DEXTENZA approval enabled management to file a Phase 2-enabling IND by YE20.â€Speaking to the possible opportunity here, both products could “provide revenue generation for physicians in the treatment of dry eyes using procedure CPT code 0356T, which could provide incentive for rapid adoption in the dry eye space that is currently valued at $5.1 billion,†in Leone’s opinion.As for the clinical and regulatory pathway, the Phase 2 trial for OTX-DED is set to kick off in 2H21, slightly after OTX-CSI, which will see a Phase 2 clinical trial evaluating two different formulations initiated by 4Q20. Based on the short treatment duration of OTX-DED, management thinks it will still be brought to market first.To this end, Leone remains optimistic about the company’s long-term growth narrative. As a result, he rates OCUL a Strong Buy along with a $15 price target. This figure implies shares could rise 89% in the year ahead. (To watch Leone’s track record, click here) Turning now to the rest of the Street, other analysts are on the same page. With 100% Street support, or 3 Buy ratings to be exact, the consensus is unanimous: OCUL is a Strong Buy. The $13.50 average price target brings the upside potential to 70%. (See OCUL stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Title: Kai Havertz To Undergo Chelsea Medical Ahead Of €80m Move Did Werner heighten expectations at Chelsea with goal vs. Spain? (1:29) Steve Nicol and Ale Moreno react to Timo Werner's superb goal in Germany's 1-1 draw with Spain. (1:29) Kai Havertz will undergo a medical on Friday, with Chelsea on the verge of completing a deal for the Bayer Leverkusen midfielder worth €80 million plus €20m in add-ons. The 21-year-old was given permission on Friday to leave the Germany national team training camp and fly to London to put the finishing touches to his deal. - Stream FC Daily on ESPN+- Insider Notebook: Man Utd boss Solskjaer vows to undo Sanchez mess Germany head coach Joachim Low confirmed he would not return for the side's Nations League match against Switzerland on Sunday, making him available for Chelsea's opening Premier League fixture on Sept. 14. • Messi makes Barca U-turn, says he'll stay• Messi's father denies €700m release clause• Havertz to undergo Chelsea medical• Sources: Sancho to Utd held up by fees• Sources: Barca's Suarez set for Juve move• Sanchez wanted to 'rip up' Utd contract• Moneyball guru buys stake in Dutch club• USMNT boss: Pulisic can play for Barca, Real "If he were to travel to Switzerland and return, I believe, he'd have to go into quarantine and the player, of course, wants a good start at Chelsea and this would be a disadvantage for him," Low said. The medical is not expected to raise any issues and the Blues are set to confirm Havertz as a Chelsea player by the end of the week, taking their summer spending spree past £200m with the acquisitions of Hakim Ziyech, Timo Werner and Ben Chilwell in addition to free signings Thiago Silva and Malang Sarr. Havertz was an unused substitute in Germany's 1-1 draw against Spain on Thursday evening. The decision not to play him was taken following consultation with Chelsea to avoid any risk of injury complicating his medical. This Medical Worker Used To Be A 'hero.' Now He Feels Hated That was five or six months ago, or perhaps another lifetime. When I talked to Parsia Jahanbani in mid-August, the warmth and goodwill were gone. Parsia works at Families Together of Orange County, a non-profit that provides medical and dental care to the underprivileged. He's an expanded-function dental assistant -- basically a dental nurse practitioner -- and he drives a giant bus called a mobile medical unit to various homeless shelters. His organization lost about one-third of its staff early in the pandemic to furloughs, resignations and other factors. The pandemic makes dental work especially dangerous. One morning, as colleagues departed, Parsia saw his 80-year-old father, the dental director, sitting behind his desk. "And I go to talk to him, 'I'm like, 'Why aren't you going home?' He's like, 'This is my ship. I'm the captain...I can't go home.' Like, 'You're 80. You're at risk. You -- if you get sick, this is it. Do you understand that?' And he starts crying." His father reluctantly went home, leaving Parsia to face his own dilemma at age 36. He has a rare and mysterious neurological condition called cluster headaches. These sporadic headaches come with seizures, and they've put him in the hospital several times. His treatment for the intermittent symptoms include immunosuppressive drugs that could increase his vulnerability to the coronavirus. More than 30 million Americans have lost their jobs this year. Millions more, including Parsia, have been forced to answer a horrifying question: Do I want or need my job so much that I'll keep doing it even if it might kill me? Parsia Jahanbani giving a coronavirus test. Parsia Jahanbani giving a coronavirus test. Parsia Jahanbani giving a coronavirus test. Parsia could recall a moment from a few years earlier, when his seizures were incapacitating. He says he made a deal with God: "Give me the health to do this and I promise to serve." And so, when the coronavirus question posed itself, Parsia answered yes. Now he wouldn't just do dental work. He'd be the one giving coronavirus tests. Sweating in his face shield and goggles and mask and full-body Tyvek suit, jamming swabs into the throats of strangers who coughed and sneezed all over him. "We knew that we were risking our lives going back to work," he said. "But I remember one day we showed up to the Salvation Army's emergency shelter and a group of our patients that are homeless, they were on a lockdown. They couldn't leave the shelter...And as I'm pulling up in the parking lot, I see five or six people standing behind the chain-link fence. And one of them was holding a pizza box. As we get closer, he kind of opens the lid of the pizza box. And on the top part of it, on the lid part of it, he had written, 'Thank you.' And the bottom part was, 'Our medical workers.' And he opened the box and kind of showed me the sign and the other four kind of clapped for us. And as I'm driving, I started crying. I started bawling. I couldn't hold it back. And I turned around and told the doctor, you know, 'This is why we're here.'" April, May, June. President Donald Trump encouraged armed protesters to rebel against mandatory shutdowns in Michigan. George Floyd was killed in Minneapolis. More than 1,000 health professionals signed a letter supporting the mass demonstrations that followed, leaving some Americans confused about which gatherings were safe. The coronavirus death toll surpassed 50,000; 100,000, 150,000. Across the political spectrum, people were some combination of sad, angry, tired, bored, sick of this whole nightmare of a decade of a year. National unity? A distant memory. Parsia kept working, although no one called him a hero anymore. Among the patients who had to get tested for work, some called the pandemic a hoax. One called Parsia a communist. "He pulled up with his car through the drive-through testing," Parsia told me. "I'm like, 'You are in the testing facility. You came to me. I didn't, like, force you to come get tested. And moreover, I -- if you don't believe in the virus and everything, then why are you getting tested?...You need to wear a mask. You need to follow the instructions.' The moment that we go to pull the swab to his face, here we go again. 'What the f**k are you doing?...Is there something on the swab? Where are you getting the swabs from? Go grab a new one. Open it in front of me. Want to make sure that you're not putting anything in my body.'" Some of the anger was justified. Test kits piled up at the lab. Some patients waited a month for results, which meant the tests were useless. If they were sick, they'd been spreading it for weeks by the time they knew. Parsia was exhausted, dehydrated, sweating in the suit for 12 hours a day. One day in August he collapsed and had to go to the hospital. Back at home, he lay awake in bed with his mind racing. He worried about infecting his wife, her parents. He thought about dying. He wrote out his will. And as he summoned the resolve to put on the Tyvek suit, Parsia thought of his father, Safaeddin Jahanbani. The captain of the ship. He'd been told to go home for his own safety at the start of the pandemic. Here's what happened next. "Every morning he would get up, shower, shave, put on his tie, and just sit by the dining table waiting for a call for him to go back to work," Parsia told me. "He wanted so bad to be a part of this and help in some way...He stayed home less than a month. Towards the end of it, he was telling me, like, 'If I don't work for much longer, you know, then I'm gonna die.' Right. Like, 'No, you're not, Dad. Come on.' Like, 'No, it's this, having a purpose in life that's keeping me going.' And I understood that. 'Cause even at 36, I feel the same...He says that's the oath that he took as a doctor, to serve, to protect. To be there for patients. Because he's like, 'Till my last breath, I'm going to be there. I'm going to see patients. I'm going to help people.'" And so they both went to work. I spoke with the father, Dr. Jahanbani, and he confirmed what his son told me. The signs didn't matter to him. Only the mission did. "This is not something to boast about, or to feel heroic," he said. "We do it very humbly." He said other workers deserved appreciation: airline pilots, cashiers in grocery stores, anyone clearing tables in restaurants. And he's right. I think of them often. All these people risking everything on a Monday morning or a Thursday night. Firefighters and meatpacking workers. Janitors, bus drivers, schoolteachers. A courageous multitude in a fracturing nation, holding us all together. Medical Marijuana, Inc. Announces Production And Warehouse Facility Expansion; Adds State-of-the-Art Manufacturing Capability And Hemp License TipRanks Billionaire Ken Griffin Snaps Up These 3 “Strong Buy†Stocks As fears of a tech bubble and stretched valuations become the talk of the town, investors are turning to Wall Street titans for guidance, namely Ken Griffin. Founding hedge fund Citadel in 1990, the firm now boasts over $35 billion worth of assets under management.As a 19-year-old sophomore at Harvard University, Griffin began trading from his dorm room with a fax machine, computer and phone. Now, the CEO of Citadel, whose net worth stands at $15.5 billion, is known as one of the Wall Street greats. Looking at the fund’s performance during the COVID crisis, it’s even more clear why Griffin has legendary status.Unlike the average hedge fund, which had a negative return of between 3-4% in the first half of 2020, Citadel’s flagship Wellington fund saw its returns land between 13-14% for the same period.Bearing this in mind, we wanted to take a closer look at three stocks Citadel snapped up recently. Using TipRanks’ database, we found out that each ticker has earned a “Strong Buy†consensus rating from the analyst community. Not to mention all three of them boast massive upside potential.AVEO Pharmaceuticals (AVEO)Hoping to provide better outcomes for patients, AVEO Pharmaceuticals advances targeted medicines for oncology and other unmet medical needs. Following an important regulatory milestone, it’s no wonder all eyes are on this healthcare name.Griffin is among those singing AVEO’s praises. Increasing its holding by a whopping 2,357%, Citadel bought up 383,720 shares in Q2. With the total position now landing at 400,003 shares, it is valued at $1,824,013.H.C. Wainwright analyst Swayampakula Ramakanth reminds investors that on June 1, the FDA accepted the NDA for tivozanib, the company's lead candidate, for review, based on the fact that the TIVO-3 study reported positive final overall survival (OS) data. In the study, AVEO’s therapy was compared to sorafenib, marketed as Nexavar by Bayer, for the treatment of advanced renal cell carcinoma (RCC) in the third and fourth-line settings.Looking more closely at the data, which was presented at the ASCO 2020 virtual meeting, the final OS analysis resulted in an overall hazard ratio (HR) of 0.97, which favored tivozanib. Ramakanth was “encouraged†by the OS results as they “suggest tivozanib at least has a similar overall relative risk of deaths compared to sorafenib.â€â€œConsidering that TIVO-3 study met both the primary endpoint of progression free survival (PFS) and the secondary endpoint of overall response rate (ORR), with comparable OS to the active comparator, we believe tivozanib would likely get a green light for the U.S. Approval, which could be a major catalyst in the next 12 months,†Ramakanth opined.Adding to the good news, the dose escalation for the Phase 1b/2 DEDUCTIVE study, evaluating tivozanib in combination with durvalumab, a monoclonal antibody against PD-L1 marketed as Imfinzi by AstraZeneca in hepatocellular carcinoma (HCC), has been wrapped up, with it progressing to Phase 2. As the CDC estimates about 33,000 patients suffer from liver cancer every year in the U.S., Ramakanth sees an additional opportunity.To this end, Ramakanth rates AVEO a Buy rating along with a $12 price target. Should his thesis play out, a potential twelve-month gain of 163% could be in the cards. (To watch Ramakanth’s track record, click here)Other analysts don’t beg to differ. 3 Buy ratings and no Holds or Sells have been assigned in the last three months. So, the word on the Street is that AVEO is a Strong Buy. The $15 average price target is more aggressive than Ramakanth’s and implies 229% upside potential. (See AVEO stock analysis on TipRanks)IDEAYA Biosciences (IDYA)Next up we have IDEAYA Biosciences, an oncology-focused precision medicine company that develops targeted therapeutics by using molecular diagnostics. Based on the strength of its technology, this name has scored several fans.Reflecting a new position for Griffin's Citadel, the fund pulled the trigger on 248,005 shares in Q2. As for the value of this holding, it comes in at $2,881,818. Writing for Northland Capital, analyst Tim Chiang believes shares are “undervalued based on the future potential of its precision medicine oncology pipeline, which targets specific biomarkers.†Expounding on this, he stated, “IDEAYA is applying its capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets.â€Part of what makes IDYA a stand-out, in Chiang’s opinion, is the fact that its preclinical programs use its synthetic lethality (SL) platform, which targets tumors with MTAP gene deletion and homologous recombination deficiency (HRD) including BRCA mutations.“We believe the longer-term upside potential with IDYA shares is significant given the potential utility of SL. The first clinically validated SL gene pair was PARP-BRCA1/2, and based on the efficacy of PARP inhibitors, the SL approach to treating cancer has achieved substantial commercial validation,†the analyst explained.To back this up, Chiang points out that several PARP inhibitors have already been approved for the treatment of tumors with BRCA and other DNA damage repair alterations, including ovarian, breast and pancreatic cancers. These inhibitors include AstraZeneca's olaparib, GlaxoSmithKline's niraparib, Pfizer's talazoparib and Clovis’ rucaparib. He added, “We estimate these four drugs generated over $1.6 billion in worldwide sales in 2019 and are expected to reach over $6 billion in sales by 2024.â€It should be noted that multiple IND filings are set to come within the next 4-12 months, with IDYA’s lead SL candidate, IDE397, which was designed to inhibit MTAP and MAT2A and thus cause the death of cancerous tumor cells, entering the clinic in 2021.It should come as no surprise, then, that Chiang joined the bulls. To start off his IDYA coverage, he puts an Outperform rating and $28 price target on the stock. This target implies a possible twelve-month rise of 141% could be on the horizon. (To watch Chiang’s track record, click here)Similarly, the rest of the Street is getting onboard. 5 Buy ratings assigned in the last three months add up to a Strong Buy analyst consensus. In addition, the $25.20 average price target puts the potential twelve-month gain at 116%. (See IDYA stock analysis on TipRanks)Ocular Therapeutix (OCUL)Using its patented bioresorbable hydrogel-based formulation technology, Ocular Therapeutix develops cutting-edge therapies for diseases and conditions of the eye. The progress of its clinical programs has caught Wall Street’s attention, with some arguing that now is the time to get in on the action.Griffin and Citadel didn’t want to miss out on an opportunity. Snapping up 161,032 shares during Q2, the hedge fund gave the holding a 272% boost. The total position is now comprised of 220,269 shares and is valued at $1,718,098.Representing Raymond James, 5-star analyst Dane Leone cites the potential to address the unmet needs in the dry eye disease indication as a key component of his bullish thesis. The company boasts two assets targeting the condition, OTX-CSI (chronic) and OTX-DED (acute). OTX-CSI incorporates the FDA-approved immunomodulator cyclosporine as the active drug in the intracanalicular insert, which is released for an estimated three months to increase tear production.When it comes to OTX-DED, Leone argues OCUL was “clever in pursuing the development of OTX-DED (a low dose form of DEXTENZA, a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus to deliver dexamethasone to the ocular surface for up to 30 days without preservatives) for the treatment of episodic dry eye, as the prior safety data from the DEXTENZA approval enabled management to file a Phase 2-enabling IND by YE20.â€Speaking to the possible opportunity here, both products could “provide revenue generation for physicians in the treatment of dry eyes using procedure CPT code 0356T, which could provide incentive for rapid adoption in the dry eye space that is currently valued at $5.1 billion,†in Leone’s opinion.As for the clinical and regulatory pathway, the Phase 2 trial for OTX-DED is set to kick off in 2H21, slightly after OTX-CSI, which will see a Phase 2 clinical trial evaluating two different formulations initiated by 4Q20. Based on the short treatment duration of OTX-DED, management thinks it will still be brought to market first.To this end, Leone remains optimistic about the company’s long-term growth narrative. As a result, he rates OCUL a Strong Buy along with a $15 price target. This figure implies shares could rise 89% in the year ahead. (To watch Leone’s track record, click here) Turning now to the rest of the Street, other analysts are on the same page. With 100% Street support, or 3 Buy ratings to be exact, the consensus is unanimous: OCUL is a Strong Buy. The $13.50 average price target brings the upside potential to 70%. (See OCUL stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Search URL Search Domain Scan URL
URL: https://google.com/
Title: "Coronavirus Vaccine Tracker" Vaccines testing safety and dosage Vaccines in expanded safety trials Vaccines in large-scale efficacy tests Vaccines approved for early or limited use Vaccines approved for full use Vaccines testing safety and dosage Vaccines in expanded safety trials Vaccines in large-scale efficacy tests Vaccines approved for early or limited use Vaccines approved for full use Vaccines testing safety and dosage Vaccines in expanded safety trials Vaccines in large-scale efficacy tests Vaccines approved for early or limited use Vaccines approved for full use Vaccines typically require years of research and testing before reaching the clinic, but scientists are racing to produce a safe and effective coronavirus vaccine by next year. Researchers are testing 37 vaccines in clinical trials on humans, and at least 91 preclinical vaccines are under active investigation in animals. Antibody produced in response to a vaccine Antibody produced in response to a vaccine Antibody produced in response to a vaccine Work began in January with the deciphering of the SARS-CoV-2 genome. The first vaccine safety trials in humans started in March, but the road ahead remains uncertain. Some trials will fail, and others may end without a clear result. But a few may succeed in stimulating the immune system to produce effective antibodies against the virus. Here is the status of all the vaccines that have reached trials in humans, along with a selection of promising vaccines still being tested in cells or animals. For an overview of different Covid-19 treatments, see our Coronavirus Drug and Treatment Tracker. New additions and recent updates: • A vaccine by Sanofi moves to Phase 1. Aug. 31 • China approved a Sinovac vaccine for limited use. Aug. 31 • Russia’s Gamaleya moves into Phase 3 testing, two weeks after the vaccine received early approval. Aug. 28 • Kazakhstan enters Phase 1. Aug. 28 The Vaccine Testing Process The development cycle of a vaccine, from lab to clinic. PRECLINICAL TESTING: Scientists test a new vaccine on cells and then give it to animals such as mice or monkeys to see if it produces an immune response. We have confirmed 91 preclinical vaccines in active development. PHASE 1 SAFETY TRIALS: Scientists give the vaccine to a small number of people to test safety and dosage as well as to confirm that it stimulates the immune system. PHASE 2 EXPANDED TRIALS: Scientists give the vaccine to hundreds of people split into groups, such as children and the elderly, to see if the vaccine acts differently in them. These trials further test the vaccine’s safety and ability to stimulate the immune system. PHASE 3 EFFICACY TRIALS: Scientists give the vaccine to thousands of people and wait to see how many become infected, compared with volunteers who received a placebo. These trials can determine if the vaccine protects against the coronavirus. In June, the F.D.A. Said that a coronavirus vaccine would have to protect at least 50% of vaccinated people to be considered effective. In addition, Phase 3 trials are large enough to reveal evidence of relatively rare side effects that might be missed in earlier studies. EARLY OR LIMITED APPROVAL: China and Russia have approved vaccines without waiting for the results of Phase 3 trials. Experts say the rushed process has serious risks. APPROVAL: Regulators in each country review the trial results and decide whether to approve the vaccine or not. During a pandemic, a vaccine may receive emergency use authorization before getting formal approval. Once a vaccine is licensed, researchers continue to monitor people who receive it to make sure it’s safe and effective. COMBINED PHASES: One way to accelerate vaccine development is to combine phases. Some coronavirus vaccines are now in Phase 1/2 trials, for example, in which they are tested for the first time on hundreds of people. (Note that our tracker would count a combined Phase 1/2 trial as both Phase 1 and Phase 2.) All vaccines Preclinical Phase 1 Phase 2 Phase 3 Approved Genetic Vaccines Vaccines that use one or more of the coronavirus’s own genes to provoke an immune response. PHASE 3 Moderna logoNational Institutes of Health logoModerna develops vaccines based on messenger RNA (mRNA) to produce viral proteins in the body. They have yet to bring one to the market. The government has bankrolled Moderna’s efforts on a coronavirus vaccine with nearly $1 billion. In partnership with National Institutes of Health, they found that the vaccine protects monkeys from the coronavirus. In March, the company put the first Covid-19 vaccine into human trials, which yielded promising results, After carrying out a Phase 2 study they launched a Phase 3 trial on July 27. The final trial will enroll 30,000 healthy people at about 89 sites around the United States. On August 11, the government awarded the company an additional $1.5 billion in exchange for 100 million doses if the vaccine proves safe and effective. In July, Moderna lost a patent dispute over some of their vaccine technology. The following month, the company stated that it could not be certain it was the first to make the inventions claimed in their patents, including its coronavirus vaccine.Updated Aug. 17 PHASE 2 PHASE 3 COMBINED PHASES BioNTech logoPfizer logoFosun Pharma logoThe German company BioNTech entered into collaborations with Pfizer, based in New York, and the Chinese drug maker Fosun Pharma to develop an mRNA vaccine. In May they launched a Phase 1/2 trial on two versions of the vaccine. They found that both versions caused volunteers to produce antibodies against SARS-CoV-2, as well as immune cells called T cells that respond to the virus. They found that one version, called BNT162b2, produced significantly fewer side effects, such as fevers and fatigue, and so they chose it to move into Phase 2/3 trials. On July 27, the companies announced the launch of a Phase 2/3 trial with 30,000 volunteers in the United States and other countries including Argentina, Brazil, and Germany. In that same month, the Trump administration awarded a $1.9 billion contract for 100 million doses to be delivered by December and the option to acquire 500 million more doses. Meanwhile, Japan made a deal for 120 million doses. In August, Pfizer said it was on track to seek regulatory review of their vaccine as early as October 2020. If approved, Pfizer has said they expect to manufacture over 1.3 billion doses of their vaccine worldwide by the end of 2021.Updated Aug. 21 PHASE 2 Zydus Cadila logoIndian vaccine-maker Zydus Cadila began testing a DNA-based vaccine in July, becoming the second company in India to enter the Covid-19 vaccine race after Bharat Biotech. They launched a Phase 2 trial on Aug. 6.Updated Aug. 6 PHASE 2 CureVac logoIn March, the Trump administration unsuccessfully tried to entice CureVac to move its research from Germany to the United States. In June, the company launched a Phase 1 trial of its mRNA vaccine, and in August it registered a Phase 2 trial. The company said its German facility can make hundreds of millions of vaccine doses a year.Updated Aug. 17 PHASE 1 PHASE 2 COMBINED PHASES Imperial College logoMorningside logoImperial College London researchers have developed a “self-amplifying†RNA vaccine, which boosts production of a viral protein to stimulate the immune system. They began Phase 1/2 trials on June 15 and have partnered with Morningside Ventures to manufacture and distribute the vaccine through a new company called VacEquity Global Health. The researchers expect to know if the vaccine is effective by the end of the year. PHASE 1 PHASE 2 COMBINED PHASES AnGes logoOsaka University logoTakara Bio logoOn June 30, the Japanese biotechnology company AnGes announced they had started Phase 1 trials on a DNA-based vaccine, developed in partnership with Osaka University and Takara Bio. They began recruiting for the trial at the end of August.Updated Aug. 27 PHASE 1 PHASE 2 COMBINED PHASES Arcturus logoDuke-NUS Medical School logoThe California-based company Arcturus Therapeutics and Duke-NUS Medical School in Singapore have developed an mRNA vaccine. The “self-replicating†design of the molecules in the vaccine led to strong immune responses in animal experiments. In August, they launched a Phase 1/2 trial at Singapore General Hospital.Updated Aug. 12 PHASE 1 Inovio logoThe American company Inovio has developed DNA-based vaccines which are delivered into the skin with electric pulses from a hand-held device. They have vaccines in clinical trials for a number of diseases, and in June they announced interim data from a Phase 1 trial on Covid-19. They found no serious adverse effects, and measured an immune response in 34 out of 36 volunteers. Inovio has yet to publish detailed results of these studies, however, and it is embroiled in several lawsuits with stockholders and a company partner. They plan to start Phase 2/3 trials by the end of the summer.Updated Aug. 10 PHASE 1 Genexine logoThe Korean company Genexine started testing the safety of a DNA-based vaccine in June. They anticipate moving to Phase 2 trials in the fall.Updated June 24 PHASE 1 Academy of Military Medical Sciences logoSuzhou Abogen Biosciences logoWalvax Biotechnology logoIn June, Chinese researchers at the Academy of Military Medical Sciences, Suzhou Abogen Biosciences and Walvax Biotechnology announced they would start their country’s first safety trials on a mRNA-based vaccine, called ARCoV. Earlier studies on monkeys reportedly showed protective effects.Updated June 26 PRECLINICAL Sanofi logoTranslate Bio logoThe French pharmaceutical company Sanofi is developing an mRNA vaccine in partnership with Translate Bio. On June 23, they announced they were planning Phase 1 trials in the fall. It would become their second Covid-19 vaccine candidate in clinical trials, along with their protein-based vaccine.Updated Sept. 3 PRECLINICAL Other genetic vaccines in active preclinical development include vaccines from: Applied DNA Sciences, EvviVax and Takis Biotech; Chula Vaccine Research Center; DIOSynVax; Elixirgen Therapeutics; Entos Pharmaceuticals; ETheRNA; Mediphage Bioceuticals; the OPENCORONA Consortia; Scancell; the Spanish National Center for Biotechnology and the Spanish National Research Council.Updated Aug. 31 Viral Vector Vaccines Vaccines that use a virus to deliver coronavirus genes into cells. The cells make viral proteins, provoking an immune response, but the virus cannot replicate. PHASE 3 APPROVED FOR LIMITED USE CanSino Biologics logoAcademy of Military Medical Sciences logoThe Chinese company CanSino Biologics developed a vaccine based on an adenovirus called Ad5, in partnership with the Institute of Biology at the country’s Academy of Military Medical Sciences. In May, they published promising results from a Phase 1 safety trial, and in July they reported that their Phase 2 trials demonstrated the vaccine produced a strong immune response. In an unprecedented move, the Chinese military approved the vaccine on June 25 for a year as a “specially needed drug.†CanSino would not say whether vaccination would be mandatory or optional for soldiers. On August 9, the Saudi health ministry announced that CanSino Biologics would run a Phase 3 trial in Saudi Arabia, and later in the month they also started a trial in Pakistan.Updated Aug. 27 PHASE 3 APPROVED FOR EARLY USE Gamaleya Research Institute logoThe Gamaleya Research Institute, part of Russia’s Ministry of Health, launched a Phase 1 trial in June of a vaccine they called Gam-Covid-Vac Lyo. It is a combination of two adenoviruses, Ad5 and Ad26, both engineered with a coronavirus gene. In July, the chair of the upper house of Russia’s Parliament said the country might start vaccine production by the end of the year. On Aug. 11, President Vladimir V. Putin announced that a Russian health care regulator had approved the vaccine, renamed Sputnik V, before Phase 3 trials had even begun. Vaccine experts decried the move as risky, and Russia later walked back the announcement, saying that the approval was a “conditional registration certificate,†which would depend on positive results from Phase 3 trials. Those trials, initially planned for just 2,000 volunteers, were expanded to 40,000.Updated Aug. 28 PHASE 2 PHASE 3 COMBINED PHASES AstraZeneca logoUniversity of Oxford logoA vaccine in development by the British-Swedish company AstraZeneca and the University of Oxford is based on a chimpanzee adenovirus called ChAdOx1. A study on monkeys found that the vaccine provided them protection. In May, the United States awarded the project $1.2 billion in support. Their Phase 1/2 trial revealed that the vaccine was safe, causing no severe side effects. It raised antibodies against the coronavirus as well as other immune defenses. The vaccine is now in Phase 2/3 trials in England and India, as well as Phase 3 trials in Brazil, South Africa, and the United States. In August the European Union reached an agreement for AstraZeneca to deliver 400 million doses if the trials yield positive results. AstraZeneca has indicated they might be able to start delivering emergency vaccines as early as October, depending on the outcome of the studies. The company has said their total manufacturing capacity for the vaccine, if approved, stands at two billion doses. India’s Serum Institute has already produced millions of doses to be used in trials.Updated Aug. 17 PHASE 1 PHASE 2 COMBINED PHASES Johnson & Johnson logoBeth Israel Deaconess Medical Center logoA decade ago, researchers at Beth Israel Deaconess Medical Center in Boston developed a method for making vaccines out of a virus called Adenovirus 26, or Ad26 for short. Johnson & Johnson developed vaccines for Ebola and other diseases with Ad26 and have now made one for the coronavirus. In March they received $456 million from the United States government to support their move towards production. The vaccine has provided protection in experiments on monkeys. Johnson & Johnson launched Phase 1/2 trials in July and will launch a Phase 3 trial with 60,000 participants in September in Latin America. In August, the federal government agreed to pay $1 billion for 100 million doses if the vaccine is approved. The company is aiming for production of at least a billion doses in 2021.Updated Aug. 21 PHASE 1 ReiThera logoLazzaro Spallanzani National Institute for Infectious Disease logoThe Italian biotechnology company ReiThera has developed a Covid-19 vaccine, called GRAd-COV2, that is based on an adenovirus that infects gorillas. Working in collaboration with the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome, they launched a Phase 1 trial at the end of July.Updated Aug. 28 PRECLINICAL Novartis logoThe Swiss company Novartis will manufacture a vaccine based on a gene therapy treatment developed by the Massachusetts Eye and Ear Hospital, Massachusetts General Hospital and the Gene Therapy Program at the University of Pennsylvania. A virus called an adeno-associated virus delivers coronavirus gene fragments into cells. Phase 1 trials are set to begin in late 2020.Updated Aug. 24 PRECLINICAL Vaxart logoVaxart’s vaccine is an oral tablet containing an adenovirus that delivers coronavirus genes. They are preparing for Phase 1 trials this summer.Updated June 26 PRECLINICAL Other viral vector vaccines in active preclinical development include vaccines from: Altimmune; the German Center for Infection Research; NantKwest; Washington University.Updated Aug. 27 Protein-Based Vaccines Vaccines that use a coronavirus protein or a protein fragment to provoke an immune response. PHASE 2 Anhui Zhifei Longcom logoInstitute of Medical Biology at the Chinese Academy of Medical Sciences logoIn July, the Chinese company Anhui Zhifei Longcom began Phase 2 trials for a vaccine that is a combination of viral proteins and an adjuvant that stimulates the immune system. The company is part of Chongqing Zhifei Biological Products and has partnered with the Chinese Academy of Medical Sciences.Updated July 10 PHASE 1 PHASE 2 COMBINED PHASES Novavax logoMaryland-based Novavax makes vaccines by sticking proteins onto microscopic particles. They’ve taken on a number of different diseases this way; their flu vaccine finished Phase 3 trials in March. The company launched trials for a Covid-19 vaccine in May, and the Coalition for Epidemic Preparedness Innovations has invested $384 million in the vaccine. In July the U.S. Government awarded $1.6 billion to support the vaccine’s clinical trials and manufacturing. On Aug. 4, Novavax announced promising results from two preliminary studies in monkeys and humans. On August 17, they launched a Phase 2 trial in South Africa. The blinded, placebo-controlled trial on 2,900 people will measure not just the safety of the vaccine but its efficacy. Larger, Phase 3 trials are expected to start in October. If the trials succeed, Novavax expects to deliver 100 million doses for use in the United States by the first quarter of 2021. In August, an executive at the company said it could make well over a billion doses a year for worldwide demand.Updated Aug. 17 PHASE 1 PHASE 2 COMBINED PHASES Finlay Vaccine Institute logoOn August 18, the head of epidemiology at Cuba’s public health ministry announced that the Finlay Vaccine Institute in Havana would start a clinical trial on a vaccine for Covid-19. The vaccine, called Soberana 1, contains a part of the spike protein, called RBD, along with an adjuvant to boost the immune response.Updated Aug. 19 PHASE 1 PHASE 2 COMBINED PHASES Vector Institute logoOn August 26, a Russian biological research center known as the Vector Institute registered a Phase 1/2 trial for a coronavirus vaccine they call EpiVacCorona. The vaccine contains small portions of viral proteins, known as peptides. According to newspaper reports, the EpiVacCorona trials had already begun by then, with plans for distribution of the vaccine by the end of the year.Updated Aug. 27 PHASE 1 Clover Biopharmaceuticals logoGSK logoDynavax logoClover Biopharmaceuticals has developed a vaccine containing a protein from coronaviruses. To further stimulate the immune system, the vaccine is being given in conjunction with so-called adjuvants made by British drugmaker GSK and the American company Dynavax. Investments from CEPI will support the development of manufacturing that could lead to the production of hundreds of millions of doses a year. PHASE 1 Vaxine logoThe Australian company Vaxine developed a vaccine that combines viral proteins with an adjuvant that stimulates the immune system. They successfully completed Phase 1 trials in July and expect to start Phase 2 trials in September.Updated July 31 PHASE 1 Medicago logoGSK logoDynavax logoCanada-based Medicago, partly funded by the cigarette maker Philip Morris, uses a species of tobacco to make vaccines. They deliver virus genes into leaves, and the plant cells then create protein shells that mimic viruses. In July, Medicago launched Phase 1 trials on a plant-based Covid-19 vaccine in combination with adjuvants from drug makers GSK and Dynavax. If the trial goes well, they plan to start Phase 2/3 trials in October.Updated July 20 PHASE 1 University of Queensland logoCSL logoA vaccine from Australia’s University of Queensland delivers viral proteins altered to draw a stronger immune response. Experiments on hamsters showed that the vaccine protected them from the coronavirus. The university launched Phase 1 trials in July, combining the proteins with an adjuvant made by CSL. If the results are positive, CSL will advance late stage clinical trials by the end of 2020. They expect to manufacture tens of millions of doses.Updated Aug. 27 PHASE 1 Kentucky BioProcessing logoA second tobacco-based vaccine is in development at Kentucky BioProcessing, an American subsidiary of British American Tobacco, the maker of Lucky Strike and other cigarettes. Like Medicago, Kentucky BioProcessing engineers a species of tobacco called Nicotiana benthamiana to make viral proteins. The company previously used this technique to make a drug called Zmapp for Ebola. After preclinical testing in the spring, they registered a Phase 1 trial for their coronavirus vaccine in July.Updated July 20 PHASE 1 Medigen logoDynavax logoTaiwan-based vaccine maker Medigen is making a vaccine made of a combination of spike proteins and an adjuvant from Dynavax. They have registered a Phase 1 trial set to start in September.Updated Aug. 31 PHASE 1 AdImmune logoTaiwan-based vaccine manufacturer Adimmune got permission to launch a Phase 1 trial on August 20. The vaccine contains the RBD section of the virus’s spike protein.Updated Aug. 20 PHASE 1 West China Hospital of Sichuan University logoIn July, researchers at West China Hospital of Sichuan University published a study in Nature describing a vaccine made from the RBD region of the spike protein that could protect mice and monkeys from the coronavirus. On August 24, they got approval to run a Phase 1 trial. To make the vaccine, researchers encode the RBD region in a gene, which they insert into a virus. They then infect insect cells with the virus, causing them to make the molecule in huge amounts.Updated Aug. 27 PHASE 1 Sanofi logoGSK logoIn addition to their mRNA vaccine, Sanofi developed a Covid-19 vaccine based on viral proteins. They produced the proteins with engineered viruses that grow inside insect cells. GSK supplemented these proteins with adjuvants that stimulate the immune system. The vaccine is based on the same design Sanofi used to create Flublok, an approved vaccine for infuenza. The companies launched a Phase 1 clinical trial in September, with plans to start Phase 3 trials in December. Even before their clinical trials began, Sanofi had negotiated several deals to supply the vaccine. They reached an agreement with the British government to provide up to 60 million doses if the vaccine succeeds in trials. Meanwhile, the United Statesagreed to pay the companies $2.1 billion for 100 million doses. In addition, Sanofi agreed to provide much of its global supply to COVAX, an international collaboration to deliver the vaccine equitably across the world. In September, Sanofi said that if their trials produced positive results they would request regulatory approval in the first half of 2021. They have plans to make up to one billion doses in 2021.Updated Sept. 3 PHASE 1 ? North Korea logoOn July 18, North Korea’s State Commission of Science and Technology announced on their web site that they had started clinical trials on a vaccine based on part of the coronavirus spike protein. It’s hard to independently determine how much truth there is in the claim from the isolated dictatorship. The commission claimed to have tested the vaccine on animals, but provided no data. What’s more, it stated that effectiveness trials would have to be carried out in another country “since there is no case of Covid-19 in DPR Korea.†That’s a claim outside experts find highly doubtful.Updated July 20 PRECLINICAL Baylor College of Medicine logoTexas Children’s Hospital Center for Vaccine Development logoAfter the SARS epidemic in 2002, Baylor College of Medicine researchers began developing a vaccine that could prevent a new outbreak. Despite promising early results, support for the research disappeared. Because the coronaviruses that cause SARS and Covid-19 are very similar, the researchers revived the project in partnership with the Texas Children’s Hospital. The researchers have found that the Covid-19 vaccine produces antibodies in mice. In August, the Indian company Biological E licensed it, saying they could potentially make a billion doses a year.Updated Aug. 27 PRECLINICAL University of Pittsburgh logoA vaccine in development by the University of Pittsburgh, called PittCoVacc, is a skin patch tipped with 400 tiny needles made of sugar. When placed on the skin, the needles dissolve and deliver virus proteins into the body. Its creators are planning to start clinical trials in late 2020.Updated Aug. 27 PRECLINICAL Other protein-based vaccines in active preclinical development include vaccines from: Adaptive Phage Therapeutics; AdaptVac and Bavarian Nordic; Applied Biotechnology Institute; Artes Biotech; Axon Neuroscience; BiOMVis and University of Trento; City College of New York and TechnoVax; COVAXX; EpiVax; GeoVax; Heat Biologics; IBio and CC-Pharming; Icosavax and University of Washington; ImmunoPrecise Antibodies; IMV; Instituto Butantan; Intravacc; IrsiCaixa; Izmir Biomedicine and Genome Center; Navarrabiomed; NidoVax; OncoGen; Oragenics; OSE Immunotherapeutics; Osivax; PDS Biotechnology; Pontifical Catholic University of Chile; Saiba; SK Bioscience; Symvivo; University of Alberta; University of Georgia and EpiVax; University of Saskatchewan and VIDO-InterVac; University of Virginia; UNSAM-CONICET; Vaxil-Bio; VBI Vaccines; Verndari; VIDO-InterVac; Voltron Therapeutics; Walter Reed Army Institute of Research; Wyss Institute and Harvard University; Yisheng Biopharma.Updated Aug. 27 Whole-Virus Vaccines Vaccines that use weakened or inactivated viruses to provoke an immune response. PHASE 3 APPROVED FOR LIMITED USE Sinovac logoThe private Chinese company Sinovac Biotech is testing an inactivated vaccine called CoronaVac. In June the company announced that Phase 1/2 trials on 743 volunteers found no severe adverse effects and produced an immune response. Sinovac then launched a Phase 3 trial in Brazil in July and another in Indonesia the following month. Reuters reported that the Chinese government gave the Sinovac vaccine an emergency approval for limited use in July. Meanwhile, Sinovac has been preparing to manufacture the vaccine, reaching an agreement to supply Indonesia with at least 40 million doses by March 2021.Updated Aug. 31 PHASE 3 Sinopharm logoWuhan logoThe Wuhan Institute of Biological Products developed an inactivated virus vaccine, which the state-owned Chinese company Sinopharm put into clinical tests. The Phase 1/2 trial showed that the vaccine produced antibodies in volunteers, some of whom experienced fevers and other side effects. They launched Phase 3 trials in the United Arab Emirates in July, and in Peru and Morocco the following month. Sinopharm’s chairman said in August that the vaccine could potentially be ready for public use by the end of 2020. Sinopharm said that the Chinese government approved one of their two inactivated virus vaccines for emergency use in July, but it was not clear which one got the approval.Updated Aug. 31 PHASE 3 Sinopharm logoSinopharm is also testing a second inactivated virus vaccine, this one developed by the Beijing Institute of Biological Products. In Phase 3 trials in the United Arab Emirates, 5,000 people are receiving the Wuhan Institute version, while another 5,000 are receiving the Beijing Institute one. Sinopharm said that the Chinese government approved one of their two inactivated virus vaccines for emergency use in July, but it was not clear which one got the approval.Updated Aug. 8 PHASE 2 Institute of Medical Biology at the Chinese Academy of Medical Sciences logoResearchers at the Institute of Medical Biology at the Chinese Academy of Medical Sciences, which has invented vaccines for polio and hepatitis A, started a Phase 2 trial of an inactivated virus vaccine in June.Updated June 23 PHASE 1 PHASE 2 COMBINED PHASES Bharat Biotech logoIndian Council of Medical Research logoNational Institute of Virology logoIn collaboration with the Indian Council of Medical Research and the National Institute of Virology, the Indian company Bharat Biotech designed a vaccine called Covaxin based on an inactivated form of the coronavirus. When the company launched Phase 1/2 trials in July, reports circulated that the vaccine would be ready by August 15. But the C.E.O. Of Bharat told reporters it would be available no sooner than early 2021.Updated July 20 PHASE 1 Merck logoThemis logoInstitut Pasteur logoThe American company Merck acquired the Austrian firm Themis Bioscience in June and is working on a vaccine originally developed at Institut Pasteur. The vaccine uses weakened measles virus to carry genetic material into patients’ cells. Researchers launched a Phase I trial in August.Updated Aug. 12 PHASE 1 Kazakhstan’s Research Institute for Biological Safety Problems logoThe central Asian nation of Kazakhstan began research on a vaccine made from inactivated coronaviruses over the summer. On August 28, their Research Institute for Biological Safety Problems registered a Phase 1 trial on the vaccine, known as QazCovid.Updated Aug. 28 PRECLINICAL Merck logoInternational AIDS Vaccine Initiative logoMerck announced in May it would develop a vaccine from vesicular stomatitis viruses, the same approach it successfully used to produce the first approved vaccine for Ebola. The company is partnering with IAVI and has received $38 million in support from the United States government. Unlike most other vaccines, this one could be taken orally. Merck and IAVI are planning a Phase 1 trial expected to start sometime in late 2020.Updated Aug. 27 PRECLINICAL Other whole-virus vaccines in active preclinical development include vaccines from: the Chumakov Center at the Russian Academy of Sciences; Codagenix; Intravacc; the Israel Institute for Biological Research; KU Leuven; Meissa Vaccines; Icahn School of Medicine at Mount Sinai; the Spanish National Center for Biotechnology and the Spanish National Research Council; Thomas Jefferson University and Bharat Biotechnology; Tonix Pharmaceuticals; University of Hong Kong; University of Pittsburgh; Valneva; Vivaldi Biosciences; Washington University; Western University.Updated Sept. 2 Repurposed Vaccines Vaccines already in use for other diseases that may also protect against Covid-19. PHASE 3 Murdoch Children’s Research Institute logoThe Bacillus Calmette-Guerin vaccine was developed in the early 1900s as a protection against tuberculosis. The Murdoch Children’s Research Institute in Australia is conducting a Phase 3 trial called the BRACE to see if the vaccine partly protects against the coronavirus. PRECLINICAL Other repurposed vaccines are in clinical trials being conducted by: the Bandim Health Project; Hôpitaux de Paris; Louisiana State University Health Sciences Center New Orleans the BADAS Study (Texas A&M University, Baylor College of Medicine, M.D. Anderson Cancer Center and Cedars-Sinai Medical Center); India’s National Institute for Research in Tuberculosis; BCG-CORONA (UMC Utrecht and Radboud University); University of Campinas; University Health Network, the Serum Institute of India, the Max Planck Institute for Infection Biology and Verity Pharmaceuticals; Oklahoma Medical Research Foundation and the University of Oklahoma; Vakzine Projekt Management.Updated Aug. 31 Note: Vaccines will be added to the tracker when they reach Phase 1, and tracked until they succeed or fail. Did we miss something? To notify The Times of new developments, send updates to vaccinetracker@nytimes.Com. Tracking the Coronavirus Additional reporting by Andrew Kramer, Carlos Tejada and Li Cao. Note: Early versions of the tracker combined two vaccines by Sinopharm into one entry. Subsequent reporting confirmed they are two different vaccines. A previous version of the tracker stated that Pfizer had reached a deal with the EU, when in fact the deal was made by AstraZeneca. Sources: World Health Organization, National Institute of Allergy and Infectious Diseases, National Center for Biotechnology Information, New England Journal of Medicine. UN: No Vaccine To Be Endorsed Before It's Safe And Effective LONDON (AP) - The head of the World Health Organization said the U.N. Health agency would not recommend any COVID-19 vaccine before it is proved safe and effective, even as Russia and China have started using their experimental vaccines before large studies have finished and other countries have proposed streamlining authorization procedures. At a press briefing on Friday, Tedros Adhanom Ghebreyesus said vaccines have been used successfully for decades, and credited them with eradicating smallpox and bringing polio to the brink of being eliminated. “I would like to assure the public that WHO will not endorse a vaccine that’s not effective and safe,†Tedros said. He said newly developed Ebola vaccines helped end the recent Ebola outbreak in Congo, noting that stopping the deadly virus was complicated by the dozens of armed groups operating in the region. Tedros appealed to people opposed to vaccination to do their own research. “The anti-vaccine movement, they can build narratives to fight against vaccines but the track record of vaccines tells its own story and people should not be confused,†he said, appealing to parents in particular. “They can have a look for themselves on how the world actually used vaccines to reduce under-5 mortality to save children.†Last week, Britain said it was preparing to revise its laws so that any effective coronavirus vaccine could be used before it was fully licensed. Russia became the first country in the world to approve a COVID-19 vaccine in August after licensing a shot that had only been tested in several dozen people. On Friday, Russian scientists published data from early studies suggesting their vaccine was safe and prompted an antibody response, but the results were limited and experts said the shot had not yet proven to work. The Russian vaccine, known as Sputnik V, is now being tested in about 40,000 people and is being offered “in parallel†to key workers like doctors and teachers. Among those who have received it are one of President Vladimir Putin’s daughters and Defense Minister Sergei Shoigu. China has reportedly begun inoculating some high-risk groups with one of its experimental coronavirus vaccine while the large studies to prove its efficacy and safety are ongoing. In July, the head of China’s Center for Disease Control and Prevention announced that he had received the shot, although he did not specify whether that was done as part of a clinical trial. ___ Follow AP pandemic coverage at http://apnews.Com/VirusOutbreak and https://apnews.Com/UnderstandingtheOutbreak Sign up for Daily Newsletters Copyright © 2020 The Washington Times, LLC. WHO Tempers Quick Vaccine Hopes The World Health Organization said Friday it did not expect widespread immunisation against the novel coronavirus until mid-2021, tempering hopes just as research revealed encouraging early results from a Russian vaccine. The virus which has killed nearly 870,000 people worldwide continues to spread, with Italy's flamboyant former prime minister Silvio Berlusconi now in hospital after becoming the latest high-profile figure to test positive for Covid-19. Across the world, governments are hoping to announce a vaccine as soon as possible against the virus, which has infected well over 26 million people, upended millions of lives and wreaked havoc on the global economy. The UN health agency welcomed the fact that a "considerable number" of vaccine candidates had entered final stage trials, which typically involve tens of thousands of people. But "in terms of realistic timelines, we are really not expecting to see widespread vaccination until the middle of next year," WHO spokeswoman Margaret Harris said. And WHO chief Tedros Adhanom Ghebreyesus said the agency would not endorse a vaccine if it is not effective and safe. - 'Trials too small' - Russia has already approved a vaccine, and research published in The Lancet medical journal on Friday said patients involved in early tests developed antibodies with "no serious adverse events". But scientists cautioned the trials were too small -- just 76 participants -- to prove safety and effectiveness. Washington has also urged US states to get ready for a potential vaccine rollout by November 1, sparking concerns President Donald Trump's administration is rushing to begin distributing a vaccine before the November 3 election. Under normal procedures, test administrators must wait for months or years to verify that vaccine candidates are safe and efficacious. But there has been massive pressure to roll out a vaccine quickly as the pandemic continues to take its toll. - Celebrities hit - Story continues Celebrities and prominent public figures have not been spared, with Berlusconi the latest to contract the coronavirus since it was first discovered in China in December last year. The list also includes three Paris Saint-Germain footballers including Brazilian star Neymar. Also on the list are movie stars Tom Hanks and more recently Robert Pattinson, whom Hollywood trade publications said contracted the disease while filming the latest Batman movie in Britain. Berlusconi spent the night in a Milan hospital where he is being treated for a lung infection but where is condition is said to be "encouraging". The 83-year-old billionaire tested positive earlier this week after returning from a holiday on Sardinia's jet-set Emerald Coast. - Workers avoiding office - All over the world, businesses and individuals are counting the cost of the pandemic, as flare-ups continue to force governments into imposing lockdowns. Even in areas where restrictions have eased, those who can work from home prefer to keep doing so rather than return to the office. In London's normally bustling centre, eateries once packed with customers are suffering. "People saw they can work from home... We can't serve someone from home," said Berat, the manager at a Turkish restaurant close to St Paul's Cathedral that only has 15 percent of its usual custom. Prime Minister Boris Johnson's government is trying to encourage Britons to return to the office, but that is easier said than done. Oil giant BP, which is slashing 10,000 jobs after the pandemic crushed energy demand and prices, is actively encouraging non-frontline staff to work from home. At Barclays, HSBC and Lloyds banks, meanwhile, much of the staff is working remotely. - Tentative recovery - It is not all bad news, though. Both the US and Canadian economies added jobs in August, in a tentative sign of recovery from the pandemic. And for businesses in specific sectors like personal protective equipment, Covid-19 has triggered such fierce demand that they are struggling to keep up. The downside? Customers must now wait nearly 600 days for their orders to be filled, compared with normal delivery of 30-40 days, said chief executive, Lim Wee Chai. In addition, with raw materials in short supply, production costs are also rising. burs-mbx/txw
Title: "Coronavirus Vaccine Tracker" Vaccines testing safety and dosage Vaccines in expanded safety trials Vaccines in large-scale efficacy tests Vaccines approved for early or limited use Vaccines approved for full use Vaccines testing safety and dosage Vaccines in expanded safety trials Vaccines in large-scale efficacy tests Vaccines approved for early or limited use Vaccines approved for full use Vaccines testing safety and dosage Vaccines in expanded safety trials Vaccines in large-scale efficacy tests Vaccines approved for early or limited use Vaccines approved for full use Vaccines typically require years of research and testing before reaching the clinic, but scientists are racing to produce a safe and effective coronavirus vaccine by next year. Researchers are testing 37 vaccines in clinical trials on humans, and at least 91 preclinical vaccines are under active investigation in animals. Antibody produced in response to a vaccine Antibody produced in response to a vaccine Antibody produced in response to a vaccine Work began in January with the deciphering of the SARS-CoV-2 genome. The first vaccine safety trials in humans started in March, but the road ahead remains uncertain. Some trials will fail, and others may end without a clear result. But a few may succeed in stimulating the immune system to produce effective antibodies against the virus. Here is the status of all the vaccines that have reached trials in humans, along with a selection of promising vaccines still being tested in cells or animals. For an overview of different Covid-19 treatments, see our Coronavirus Drug and Treatment Tracker. New additions and recent updates: • A vaccine by Sanofi moves to Phase 1. Aug. 31 • China approved a Sinovac vaccine for limited use. Aug. 31 • Russia’s Gamaleya moves into Phase 3 testing, two weeks after the vaccine received early approval. Aug. 28 • Kazakhstan enters Phase 1. Aug. 28 The Vaccine Testing Process The development cycle of a vaccine, from lab to clinic. PRECLINICAL TESTING: Scientists test a new vaccine on cells and then give it to animals such as mice or monkeys to see if it produces an immune response. We have confirmed 91 preclinical vaccines in active development. PHASE 1 SAFETY TRIALS: Scientists give the vaccine to a small number of people to test safety and dosage as well as to confirm that it stimulates the immune system. PHASE 2 EXPANDED TRIALS: Scientists give the vaccine to hundreds of people split into groups, such as children and the elderly, to see if the vaccine acts differently in them. These trials further test the vaccine’s safety and ability to stimulate the immune system. PHASE 3 EFFICACY TRIALS: Scientists give the vaccine to thousands of people and wait to see how many become infected, compared with volunteers who received a placebo. These trials can determine if the vaccine protects against the coronavirus. In June, the F.D.A. Said that a coronavirus vaccine would have to protect at least 50% of vaccinated people to be considered effective. In addition, Phase 3 trials are large enough to reveal evidence of relatively rare side effects that might be missed in earlier studies. EARLY OR LIMITED APPROVAL: China and Russia have approved vaccines without waiting for the results of Phase 3 trials. Experts say the rushed process has serious risks. APPROVAL: Regulators in each country review the trial results and decide whether to approve the vaccine or not. During a pandemic, a vaccine may receive emergency use authorization before getting formal approval. Once a vaccine is licensed, researchers continue to monitor people who receive it to make sure it’s safe and effective. COMBINED PHASES: One way to accelerate vaccine development is to combine phases. Some coronavirus vaccines are now in Phase 1/2 trials, for example, in which they are tested for the first time on hundreds of people. (Note that our tracker would count a combined Phase 1/2 trial as both Phase 1 and Phase 2.) All vaccines Preclinical Phase 1 Phase 2 Phase 3 Approved Genetic Vaccines Vaccines that use one or more of the coronavirus’s own genes to provoke an immune response. PHASE 3 Moderna logoNational Institutes of Health logoModerna develops vaccines based on messenger RNA (mRNA) to produce viral proteins in the body. They have yet to bring one to the market. The government has bankrolled Moderna’s efforts on a coronavirus vaccine with nearly $1 billion. In partnership with National Institutes of Health, they found that the vaccine protects monkeys from the coronavirus. In March, the company put the first Covid-19 vaccine into human trials, which yielded promising results, After carrying out a Phase 2 study they launched a Phase 3 trial on July 27. The final trial will enroll 30,000 healthy people at about 89 sites around the United States. On August 11, the government awarded the company an additional $1.5 billion in exchange for 100 million doses if the vaccine proves safe and effective. In July, Moderna lost a patent dispute over some of their vaccine technology. The following month, the company stated that it could not be certain it was the first to make the inventions claimed in their patents, including its coronavirus vaccine.Updated Aug. 17 PHASE 2 PHASE 3 COMBINED PHASES BioNTech logoPfizer logoFosun Pharma logoThe German company BioNTech entered into collaborations with Pfizer, based in New York, and the Chinese drug maker Fosun Pharma to develop an mRNA vaccine. In May they launched a Phase 1/2 trial on two versions of the vaccine. They found that both versions caused volunteers to produce antibodies against SARS-CoV-2, as well as immune cells called T cells that respond to the virus. They found that one version, called BNT162b2, produced significantly fewer side effects, such as fevers and fatigue, and so they chose it to move into Phase 2/3 trials. On July 27, the companies announced the launch of a Phase 2/3 trial with 30,000 volunteers in the United States and other countries including Argentina, Brazil, and Germany. In that same month, the Trump administration awarded a $1.9 billion contract for 100 million doses to be delivered by December and the option to acquire 500 million more doses. Meanwhile, Japan made a deal for 120 million doses. In August, Pfizer said it was on track to seek regulatory review of their vaccine as early as October 2020. If approved, Pfizer has said they expect to manufacture over 1.3 billion doses of their vaccine worldwide by the end of 2021.Updated Aug. 21 PHASE 2 Zydus Cadila logoIndian vaccine-maker Zydus Cadila began testing a DNA-based vaccine in July, becoming the second company in India to enter the Covid-19 vaccine race after Bharat Biotech. They launched a Phase 2 trial on Aug. 6.Updated Aug. 6 PHASE 2 CureVac logoIn March, the Trump administration unsuccessfully tried to entice CureVac to move its research from Germany to the United States. In June, the company launched a Phase 1 trial of its mRNA vaccine, and in August it registered a Phase 2 trial. The company said its German facility can make hundreds of millions of vaccine doses a year.Updated Aug. 17 PHASE 1 PHASE 2 COMBINED PHASES Imperial College logoMorningside logoImperial College London researchers have developed a “self-amplifying†RNA vaccine, which boosts production of a viral protein to stimulate the immune system. They began Phase 1/2 trials on June 15 and have partnered with Morningside Ventures to manufacture and distribute the vaccine through a new company called VacEquity Global Health. The researchers expect to know if the vaccine is effective by the end of the year. PHASE 1 PHASE 2 COMBINED PHASES AnGes logoOsaka University logoTakara Bio logoOn June 30, the Japanese biotechnology company AnGes announced they had started Phase 1 trials on a DNA-based vaccine, developed in partnership with Osaka University and Takara Bio. They began recruiting for the trial at the end of August.Updated Aug. 27 PHASE 1 PHASE 2 COMBINED PHASES Arcturus logoDuke-NUS Medical School logoThe California-based company Arcturus Therapeutics and Duke-NUS Medical School in Singapore have developed an mRNA vaccine. The “self-replicating†design of the molecules in the vaccine led to strong immune responses in animal experiments. In August, they launched a Phase 1/2 trial at Singapore General Hospital.Updated Aug. 12 PHASE 1 Inovio logoThe American company Inovio has developed DNA-based vaccines which are delivered into the skin with electric pulses from a hand-held device. They have vaccines in clinical trials for a number of diseases, and in June they announced interim data from a Phase 1 trial on Covid-19. They found no serious adverse effects, and measured an immune response in 34 out of 36 volunteers. Inovio has yet to publish detailed results of these studies, however, and it is embroiled in several lawsuits with stockholders and a company partner. They plan to start Phase 2/3 trials by the end of the summer.Updated Aug. 10 PHASE 1 Genexine logoThe Korean company Genexine started testing the safety of a DNA-based vaccine in June. They anticipate moving to Phase 2 trials in the fall.Updated June 24 PHASE 1 Academy of Military Medical Sciences logoSuzhou Abogen Biosciences logoWalvax Biotechnology logoIn June, Chinese researchers at the Academy of Military Medical Sciences, Suzhou Abogen Biosciences and Walvax Biotechnology announced they would start their country’s first safety trials on a mRNA-based vaccine, called ARCoV. Earlier studies on monkeys reportedly showed protective effects.Updated June 26 PRECLINICAL Sanofi logoTranslate Bio logoThe French pharmaceutical company Sanofi is developing an mRNA vaccine in partnership with Translate Bio. On June 23, they announced they were planning Phase 1 trials in the fall. It would become their second Covid-19 vaccine candidate in clinical trials, along with their protein-based vaccine.Updated Sept. 3 PRECLINICAL Other genetic vaccines in active preclinical development include vaccines from: Applied DNA Sciences, EvviVax and Takis Biotech; Chula Vaccine Research Center; DIOSynVax; Elixirgen Therapeutics; Entos Pharmaceuticals; ETheRNA; Mediphage Bioceuticals; the OPENCORONA Consortia; Scancell; the Spanish National Center for Biotechnology and the Spanish National Research Council.Updated Aug. 31 Viral Vector Vaccines Vaccines that use a virus to deliver coronavirus genes into cells. The cells make viral proteins, provoking an immune response, but the virus cannot replicate. PHASE 3 APPROVED FOR LIMITED USE CanSino Biologics logoAcademy of Military Medical Sciences logoThe Chinese company CanSino Biologics developed a vaccine based on an adenovirus called Ad5, in partnership with the Institute of Biology at the country’s Academy of Military Medical Sciences. In May, they published promising results from a Phase 1 safety trial, and in July they reported that their Phase 2 trials demonstrated the vaccine produced a strong immune response. In an unprecedented move, the Chinese military approved the vaccine on June 25 for a year as a “specially needed drug.†CanSino would not say whether vaccination would be mandatory or optional for soldiers. On August 9, the Saudi health ministry announced that CanSino Biologics would run a Phase 3 trial in Saudi Arabia, and later in the month they also started a trial in Pakistan.Updated Aug. 27 PHASE 3 APPROVED FOR EARLY USE Gamaleya Research Institute logoThe Gamaleya Research Institute, part of Russia’s Ministry of Health, launched a Phase 1 trial in June of a vaccine they called Gam-Covid-Vac Lyo. It is a combination of two adenoviruses, Ad5 and Ad26, both engineered with a coronavirus gene. In July, the chair of the upper house of Russia’s Parliament said the country might start vaccine production by the end of the year. On Aug. 11, President Vladimir V. Putin announced that a Russian health care regulator had approved the vaccine, renamed Sputnik V, before Phase 3 trials had even begun. Vaccine experts decried the move as risky, and Russia later walked back the announcement, saying that the approval was a “conditional registration certificate,†which would depend on positive results from Phase 3 trials. Those trials, initially planned for just 2,000 volunteers, were expanded to 40,000.Updated Aug. 28 PHASE 2 PHASE 3 COMBINED PHASES AstraZeneca logoUniversity of Oxford logoA vaccine in development by the British-Swedish company AstraZeneca and the University of Oxford is based on a chimpanzee adenovirus called ChAdOx1. A study on monkeys found that the vaccine provided them protection. In May, the United States awarded the project $1.2 billion in support. Their Phase 1/2 trial revealed that the vaccine was safe, causing no severe side effects. It raised antibodies against the coronavirus as well as other immune defenses. The vaccine is now in Phase 2/3 trials in England and India, as well as Phase 3 trials in Brazil, South Africa, and the United States. In August the European Union reached an agreement for AstraZeneca to deliver 400 million doses if the trials yield positive results. AstraZeneca has indicated they might be able to start delivering emergency vaccines as early as October, depending on the outcome of the studies. The company has said their total manufacturing capacity for the vaccine, if approved, stands at two billion doses. India’s Serum Institute has already produced millions of doses to be used in trials.Updated Aug. 17 PHASE 1 PHASE 2 COMBINED PHASES Johnson & Johnson logoBeth Israel Deaconess Medical Center logoA decade ago, researchers at Beth Israel Deaconess Medical Center in Boston developed a method for making vaccines out of a virus called Adenovirus 26, or Ad26 for short. Johnson & Johnson developed vaccines for Ebola and other diseases with Ad26 and have now made one for the coronavirus. In March they received $456 million from the United States government to support their move towards production. The vaccine has provided protection in experiments on monkeys. Johnson & Johnson launched Phase 1/2 trials in July and will launch a Phase 3 trial with 60,000 participants in September in Latin America. In August, the federal government agreed to pay $1 billion for 100 million doses if the vaccine is approved. The company is aiming for production of at least a billion doses in 2021.Updated Aug. 21 PHASE 1 ReiThera logoLazzaro Spallanzani National Institute for Infectious Disease logoThe Italian biotechnology company ReiThera has developed a Covid-19 vaccine, called GRAd-COV2, that is based on an adenovirus that infects gorillas. Working in collaboration with the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome, they launched a Phase 1 trial at the end of July.Updated Aug. 28 PRECLINICAL Novartis logoThe Swiss company Novartis will manufacture a vaccine based on a gene therapy treatment developed by the Massachusetts Eye and Ear Hospital, Massachusetts General Hospital and the Gene Therapy Program at the University of Pennsylvania. A virus called an adeno-associated virus delivers coronavirus gene fragments into cells. Phase 1 trials are set to begin in late 2020.Updated Aug. 24 PRECLINICAL Vaxart logoVaxart’s vaccine is an oral tablet containing an adenovirus that delivers coronavirus genes. They are preparing for Phase 1 trials this summer.Updated June 26 PRECLINICAL Other viral vector vaccines in active preclinical development include vaccines from: Altimmune; the German Center for Infection Research; NantKwest; Washington University.Updated Aug. 27 Protein-Based Vaccines Vaccines that use a coronavirus protein or a protein fragment to provoke an immune response. PHASE 2 Anhui Zhifei Longcom logoInstitute of Medical Biology at the Chinese Academy of Medical Sciences logoIn July, the Chinese company Anhui Zhifei Longcom began Phase 2 trials for a vaccine that is a combination of viral proteins and an adjuvant that stimulates the immune system. The company is part of Chongqing Zhifei Biological Products and has partnered with the Chinese Academy of Medical Sciences.Updated July 10 PHASE 1 PHASE 2 COMBINED PHASES Novavax logoMaryland-based Novavax makes vaccines by sticking proteins onto microscopic particles. They’ve taken on a number of different diseases this way; their flu vaccine finished Phase 3 trials in March. The company launched trials for a Covid-19 vaccine in May, and the Coalition for Epidemic Preparedness Innovations has invested $384 million in the vaccine. In July the U.S. Government awarded $1.6 billion to support the vaccine’s clinical trials and manufacturing. On Aug. 4, Novavax announced promising results from two preliminary studies in monkeys and humans. On August 17, they launched a Phase 2 trial in South Africa. The blinded, placebo-controlled trial on 2,900 people will measure not just the safety of the vaccine but its efficacy. Larger, Phase 3 trials are expected to start in October. If the trials succeed, Novavax expects to deliver 100 million doses for use in the United States by the first quarter of 2021. In August, an executive at the company said it could make well over a billion doses a year for worldwide demand.Updated Aug. 17 PHASE 1 PHASE 2 COMBINED PHASES Finlay Vaccine Institute logoOn August 18, the head of epidemiology at Cuba’s public health ministry announced that the Finlay Vaccine Institute in Havana would start a clinical trial on a vaccine for Covid-19. The vaccine, called Soberana 1, contains a part of the spike protein, called RBD, along with an adjuvant to boost the immune response.Updated Aug. 19 PHASE 1 PHASE 2 COMBINED PHASES Vector Institute logoOn August 26, a Russian biological research center known as the Vector Institute registered a Phase 1/2 trial for a coronavirus vaccine they call EpiVacCorona. The vaccine contains small portions of viral proteins, known as peptides. According to newspaper reports, the EpiVacCorona trials had already begun by then, with plans for distribution of the vaccine by the end of the year.Updated Aug. 27 PHASE 1 Clover Biopharmaceuticals logoGSK logoDynavax logoClover Biopharmaceuticals has developed a vaccine containing a protein from coronaviruses. To further stimulate the immune system, the vaccine is being given in conjunction with so-called adjuvants made by British drugmaker GSK and the American company Dynavax. Investments from CEPI will support the development of manufacturing that could lead to the production of hundreds of millions of doses a year. PHASE 1 Vaxine logoThe Australian company Vaxine developed a vaccine that combines viral proteins with an adjuvant that stimulates the immune system. They successfully completed Phase 1 trials in July and expect to start Phase 2 trials in September.Updated July 31 PHASE 1 Medicago logoGSK logoDynavax logoCanada-based Medicago, partly funded by the cigarette maker Philip Morris, uses a species of tobacco to make vaccines. They deliver virus genes into leaves, and the plant cells then create protein shells that mimic viruses. In July, Medicago launched Phase 1 trials on a plant-based Covid-19 vaccine in combination with adjuvants from drug makers GSK and Dynavax. If the trial goes well, they plan to start Phase 2/3 trials in October.Updated July 20 PHASE 1 University of Queensland logoCSL logoA vaccine from Australia’s University of Queensland delivers viral proteins altered to draw a stronger immune response. Experiments on hamsters showed that the vaccine protected them from the coronavirus. The university launched Phase 1 trials in July, combining the proteins with an adjuvant made by CSL. If the results are positive, CSL will advance late stage clinical trials by the end of 2020. They expect to manufacture tens of millions of doses.Updated Aug. 27 PHASE 1 Kentucky BioProcessing logoA second tobacco-based vaccine is in development at Kentucky BioProcessing, an American subsidiary of British American Tobacco, the maker of Lucky Strike and other cigarettes. Like Medicago, Kentucky BioProcessing engineers a species of tobacco called Nicotiana benthamiana to make viral proteins. The company previously used this technique to make a drug called Zmapp for Ebola. After preclinical testing in the spring, they registered a Phase 1 trial for their coronavirus vaccine in July.Updated July 20 PHASE 1 Medigen logoDynavax logoTaiwan-based vaccine maker Medigen is making a vaccine made of a combination of spike proteins and an adjuvant from Dynavax. They have registered a Phase 1 trial set to start in September.Updated Aug. 31 PHASE 1 AdImmune logoTaiwan-based vaccine manufacturer Adimmune got permission to launch a Phase 1 trial on August 20. The vaccine contains the RBD section of the virus’s spike protein.Updated Aug. 20 PHASE 1 West China Hospital of Sichuan University logoIn July, researchers at West China Hospital of Sichuan University published a study in Nature describing a vaccine made from the RBD region of the spike protein that could protect mice and monkeys from the coronavirus. On August 24, they got approval to run a Phase 1 trial. To make the vaccine, researchers encode the RBD region in a gene, which they insert into a virus. They then infect insect cells with the virus, causing them to make the molecule in huge amounts.Updated Aug. 27 PHASE 1 Sanofi logoGSK logoIn addition to their mRNA vaccine, Sanofi developed a Covid-19 vaccine based on viral proteins. They produced the proteins with engineered viruses that grow inside insect cells. GSK supplemented these proteins with adjuvants that stimulate the immune system. The vaccine is based on the same design Sanofi used to create Flublok, an approved vaccine for infuenza. The companies launched a Phase 1 clinical trial in September, with plans to start Phase 3 trials in December. Even before their clinical trials began, Sanofi had negotiated several deals to supply the vaccine. They reached an agreement with the British government to provide up to 60 million doses if the vaccine succeeds in trials. Meanwhile, the United Statesagreed to pay the companies $2.1 billion for 100 million doses. In addition, Sanofi agreed to provide much of its global supply to COVAX, an international collaboration to deliver the vaccine equitably across the world. In September, Sanofi said that if their trials produced positive results they would request regulatory approval in the first half of 2021. They have plans to make up to one billion doses in 2021.Updated Sept. 3 PHASE 1 ? North Korea logoOn July 18, North Korea’s State Commission of Science and Technology announced on their web site that they had started clinical trials on a vaccine based on part of the coronavirus spike protein. It’s hard to independently determine how much truth there is in the claim from the isolated dictatorship. The commission claimed to have tested the vaccine on animals, but provided no data. What’s more, it stated that effectiveness trials would have to be carried out in another country “since there is no case of Covid-19 in DPR Korea.†That’s a claim outside experts find highly doubtful.Updated July 20 PRECLINICAL Baylor College of Medicine logoTexas Children’s Hospital Center for Vaccine Development logoAfter the SARS epidemic in 2002, Baylor College of Medicine researchers began developing a vaccine that could prevent a new outbreak. Despite promising early results, support for the research disappeared. Because the coronaviruses that cause SARS and Covid-19 are very similar, the researchers revived the project in partnership with the Texas Children’s Hospital. The researchers have found that the Covid-19 vaccine produces antibodies in mice. In August, the Indian company Biological E licensed it, saying they could potentially make a billion doses a year.Updated Aug. 27 PRECLINICAL University of Pittsburgh logoA vaccine in development by the University of Pittsburgh, called PittCoVacc, is a skin patch tipped with 400 tiny needles made of sugar. When placed on the skin, the needles dissolve and deliver virus proteins into the body. Its creators are planning to start clinical trials in late 2020.Updated Aug. 27 PRECLINICAL Other protein-based vaccines in active preclinical development include vaccines from: Adaptive Phage Therapeutics; AdaptVac and Bavarian Nordic; Applied Biotechnology Institute; Artes Biotech; Axon Neuroscience; BiOMVis and University of Trento; City College of New York and TechnoVax; COVAXX; EpiVax; GeoVax; Heat Biologics; IBio and CC-Pharming; Icosavax and University of Washington; ImmunoPrecise Antibodies; IMV; Instituto Butantan; Intravacc; IrsiCaixa; Izmir Biomedicine and Genome Center; Navarrabiomed; NidoVax; OncoGen; Oragenics; OSE Immunotherapeutics; Osivax; PDS Biotechnology; Pontifical Catholic University of Chile; Saiba; SK Bioscience; Symvivo; University of Alberta; University of Georgia and EpiVax; University of Saskatchewan and VIDO-InterVac; University of Virginia; UNSAM-CONICET; Vaxil-Bio; VBI Vaccines; Verndari; VIDO-InterVac; Voltron Therapeutics; Walter Reed Army Institute of Research; Wyss Institute and Harvard University; Yisheng Biopharma.Updated Aug. 27 Whole-Virus Vaccines Vaccines that use weakened or inactivated viruses to provoke an immune response. PHASE 3 APPROVED FOR LIMITED USE Sinovac logoThe private Chinese company Sinovac Biotech is testing an inactivated vaccine called CoronaVac. In June the company announced that Phase 1/2 trials on 743 volunteers found no severe adverse effects and produced an immune response. Sinovac then launched a Phase 3 trial in Brazil in July and another in Indonesia the following month. Reuters reported that the Chinese government gave the Sinovac vaccine an emergency approval for limited use in July. Meanwhile, Sinovac has been preparing to manufacture the vaccine, reaching an agreement to supply Indonesia with at least 40 million doses by March 2021.Updated Aug. 31 PHASE 3 Sinopharm logoWuhan logoThe Wuhan Institute of Biological Products developed an inactivated virus vaccine, which the state-owned Chinese company Sinopharm put into clinical tests. The Phase 1/2 trial showed that the vaccine produced antibodies in volunteers, some of whom experienced fevers and other side effects. They launched Phase 3 trials in the United Arab Emirates in July, and in Peru and Morocco the following month. Sinopharm’s chairman said in August that the vaccine could potentially be ready for public use by the end of 2020. Sinopharm said that the Chinese government approved one of their two inactivated virus vaccines for emergency use in July, but it was not clear which one got the approval.Updated Aug. 31 PHASE 3 Sinopharm logoSinopharm is also testing a second inactivated virus vaccine, this one developed by the Beijing Institute of Biological Products. In Phase 3 trials in the United Arab Emirates, 5,000 people are receiving the Wuhan Institute version, while another 5,000 are receiving the Beijing Institute one. Sinopharm said that the Chinese government approved one of their two inactivated virus vaccines for emergency use in July, but it was not clear which one got the approval.Updated Aug. 8 PHASE 2 Institute of Medical Biology at the Chinese Academy of Medical Sciences logoResearchers at the Institute of Medical Biology at the Chinese Academy of Medical Sciences, which has invented vaccines for polio and hepatitis A, started a Phase 2 trial of an inactivated virus vaccine in June.Updated June 23 PHASE 1 PHASE 2 COMBINED PHASES Bharat Biotech logoIndian Council of Medical Research logoNational Institute of Virology logoIn collaboration with the Indian Council of Medical Research and the National Institute of Virology, the Indian company Bharat Biotech designed a vaccine called Covaxin based on an inactivated form of the coronavirus. When the company launched Phase 1/2 trials in July, reports circulated that the vaccine would be ready by August 15. But the C.E.O. Of Bharat told reporters it would be available no sooner than early 2021.Updated July 20 PHASE 1 Merck logoThemis logoInstitut Pasteur logoThe American company Merck acquired the Austrian firm Themis Bioscience in June and is working on a vaccine originally developed at Institut Pasteur. The vaccine uses weakened measles virus to carry genetic material into patients’ cells. Researchers launched a Phase I trial in August.Updated Aug. 12 PHASE 1 Kazakhstan’s Research Institute for Biological Safety Problems logoThe central Asian nation of Kazakhstan began research on a vaccine made from inactivated coronaviruses over the summer. On August 28, their Research Institute for Biological Safety Problems registered a Phase 1 trial on the vaccine, known as QazCovid.Updated Aug. 28 PRECLINICAL Merck logoInternational AIDS Vaccine Initiative logoMerck announced in May it would develop a vaccine from vesicular stomatitis viruses, the same approach it successfully used to produce the first approved vaccine for Ebola. The company is partnering with IAVI and has received $38 million in support from the United States government. Unlike most other vaccines, this one could be taken orally. Merck and IAVI are planning a Phase 1 trial expected to start sometime in late 2020.Updated Aug. 27 PRECLINICAL Other whole-virus vaccines in active preclinical development include vaccines from: the Chumakov Center at the Russian Academy of Sciences; Codagenix; Intravacc; the Israel Institute for Biological Research; KU Leuven; Meissa Vaccines; Icahn School of Medicine at Mount Sinai; the Spanish National Center for Biotechnology and the Spanish National Research Council; Thomas Jefferson University and Bharat Biotechnology; Tonix Pharmaceuticals; University of Hong Kong; University of Pittsburgh; Valneva; Vivaldi Biosciences; Washington University; Western University.Updated Sept. 2 Repurposed Vaccines Vaccines already in use for other diseases that may also protect against Covid-19. PHASE 3 Murdoch Children’s Research Institute logoThe Bacillus Calmette-Guerin vaccine was developed in the early 1900s as a protection against tuberculosis. The Murdoch Children’s Research Institute in Australia is conducting a Phase 3 trial called the BRACE to see if the vaccine partly protects against the coronavirus. PRECLINICAL Other repurposed vaccines are in clinical trials being conducted by: the Bandim Health Project; Hôpitaux de Paris; Louisiana State University Health Sciences Center New Orleans the BADAS Study (Texas A&M University, Baylor College of Medicine, M.D. Anderson Cancer Center and Cedars-Sinai Medical Center); India’s National Institute for Research in Tuberculosis; BCG-CORONA (UMC Utrecht and Radboud University); University of Campinas; University Health Network, the Serum Institute of India, the Max Planck Institute for Infection Biology and Verity Pharmaceuticals; Oklahoma Medical Research Foundation and the University of Oklahoma; Vakzine Projekt Management.Updated Aug. 31 Note: Vaccines will be added to the tracker when they reach Phase 1, and tracked until they succeed or fail. Did we miss something? To notify The Times of new developments, send updates to vaccinetracker@nytimes.Com. Tracking the Coronavirus Additional reporting by Andrew Kramer, Carlos Tejada and Li Cao. Note: Early versions of the tracker combined two vaccines by Sinopharm into one entry. Subsequent reporting confirmed they are two different vaccines. A previous version of the tracker stated that Pfizer had reached a deal with the EU, when in fact the deal was made by AstraZeneca. Sources: World Health Organization, National Institute of Allergy and Infectious Diseases, National Center for Biotechnology Information, New England Journal of Medicine. UN: No Vaccine To Be Endorsed Before It's Safe And Effective LONDON (AP) - The head of the World Health Organization said the U.N. Health agency would not recommend any COVID-19 vaccine before it is proved safe and effective, even as Russia and China have started using their experimental vaccines before large studies have finished and other countries have proposed streamlining authorization procedures. At a press briefing on Friday, Tedros Adhanom Ghebreyesus said vaccines have been used successfully for decades, and credited them with eradicating smallpox and bringing polio to the brink of being eliminated. “I would like to assure the public that WHO will not endorse a vaccine that’s not effective and safe,†Tedros said. He said newly developed Ebola vaccines helped end the recent Ebola outbreak in Congo, noting that stopping the deadly virus was complicated by the dozens of armed groups operating in the region. Tedros appealed to people opposed to vaccination to do their own research. “The anti-vaccine movement, they can build narratives to fight against vaccines but the track record of vaccines tells its own story and people should not be confused,†he said, appealing to parents in particular. “They can have a look for themselves on how the world actually used vaccines to reduce under-5 mortality to save children.†Last week, Britain said it was preparing to revise its laws so that any effective coronavirus vaccine could be used before it was fully licensed. Russia became the first country in the world to approve a COVID-19 vaccine in August after licensing a shot that had only been tested in several dozen people. On Friday, Russian scientists published data from early studies suggesting their vaccine was safe and prompted an antibody response, but the results were limited and experts said the shot had not yet proven to work. The Russian vaccine, known as Sputnik V, is now being tested in about 40,000 people and is being offered “in parallel†to key workers like doctors and teachers. Among those who have received it are one of President Vladimir Putin’s daughters and Defense Minister Sergei Shoigu. China has reportedly begun inoculating some high-risk groups with one of its experimental coronavirus vaccine while the large studies to prove its efficacy and safety are ongoing. In July, the head of China’s Center for Disease Control and Prevention announced that he had received the shot, although he did not specify whether that was done as part of a clinical trial. ___ Follow AP pandemic coverage at http://apnews.Com/VirusOutbreak and https://apnews.Com/UnderstandingtheOutbreak Sign up for Daily Newsletters Copyright © 2020 The Washington Times, LLC. WHO Tempers Quick Vaccine Hopes The World Health Organization said Friday it did not expect widespread immunisation against the novel coronavirus until mid-2021, tempering hopes just as research revealed encouraging early results from a Russian vaccine. The virus which has killed nearly 870,000 people worldwide continues to spread, with Italy's flamboyant former prime minister Silvio Berlusconi now in hospital after becoming the latest high-profile figure to test positive for Covid-19. Across the world, governments are hoping to announce a vaccine as soon as possible against the virus, which has infected well over 26 million people, upended millions of lives and wreaked havoc on the global economy. The UN health agency welcomed the fact that a "considerable number" of vaccine candidates had entered final stage trials, which typically involve tens of thousands of people. But "in terms of realistic timelines, we are really not expecting to see widespread vaccination until the middle of next year," WHO spokeswoman Margaret Harris said. And WHO chief Tedros Adhanom Ghebreyesus said the agency would not endorse a vaccine if it is not effective and safe. - 'Trials too small' - Russia has already approved a vaccine, and research published in The Lancet medical journal on Friday said patients involved in early tests developed antibodies with "no serious adverse events". But scientists cautioned the trials were too small -- just 76 participants -- to prove safety and effectiveness. Washington has also urged US states to get ready for a potential vaccine rollout by November 1, sparking concerns President Donald Trump's administration is rushing to begin distributing a vaccine before the November 3 election. Under normal procedures, test administrators must wait for months or years to verify that vaccine candidates are safe and efficacious. But there has been massive pressure to roll out a vaccine quickly as the pandemic continues to take its toll. - Celebrities hit - Story continues Celebrities and prominent public figures have not been spared, with Berlusconi the latest to contract the coronavirus since it was first discovered in China in December last year. The list also includes three Paris Saint-Germain footballers including Brazilian star Neymar. Also on the list are movie stars Tom Hanks and more recently Robert Pattinson, whom Hollywood trade publications said contracted the disease while filming the latest Batman movie in Britain. Berlusconi spent the night in a Milan hospital where he is being treated for a lung infection but where is condition is said to be "encouraging". The 83-year-old billionaire tested positive earlier this week after returning from a holiday on Sardinia's jet-set Emerald Coast. - Workers avoiding office - All over the world, businesses and individuals are counting the cost of the pandemic, as flare-ups continue to force governments into imposing lockdowns. Even in areas where restrictions have eased, those who can work from home prefer to keep doing so rather than return to the office. In London's normally bustling centre, eateries once packed with customers are suffering. "People saw they can work from home... We can't serve someone from home," said Berat, the manager at a Turkish restaurant close to St Paul's Cathedral that only has 15 percent of its usual custom. Prime Minister Boris Johnson's government is trying to encourage Britons to return to the office, but that is easier said than done. Oil giant BP, which is slashing 10,000 jobs after the pandemic crushed energy demand and prices, is actively encouraging non-frontline staff to work from home. At Barclays, HSBC and Lloyds banks, meanwhile, much of the staff is working remotely. - Tentative recovery - It is not all bad news, though. Both the US and Canadian economies added jobs in August, in a tentative sign of recovery from the pandemic. And for businesses in specific sectors like personal protective equipment, Covid-19 has triggered such fierce demand that they are struggling to keep up. The downside? Customers must now wait nearly 600 days for their orders to be filled, compared with normal delivery of 30-40 days, said chief executive, Lim Wee Chai. In addition, with raw materials in short supply, production costs are also rising. burs-mbx/txw
Search URL Search Domain Scan URL
Page URL History
This captures the URL locations of the websites, including HTTP redirects and client-side redirects via JavaScript or Meta fields.
-
http://coviduvlamp.com/
HTTP 301
https://coviduvlamp.com/ Page URL
Redirected requests
There were HTTP redirect chains for the following requests:
14 HTTP transactions
| Method Protocol |
Resource Path |
Size x-fer |
Type MIME-Type |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
GET H2 |
Primary Request
/
coviduvlamp.com/ Redirect Chain
|
112 KB 52 KB |
Document
text/html |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
Redirect headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
element.js
translate.google.com/translate_a/ |
2 KB 1 KB |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
auth.php
www.freevisitorcounters.com/ |
2 KB 1 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
1
www.freevisitorcounters.com/en/home/counter/741796/t/ |
220 B 299 B |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
translateelement.css
translate.googleapis.com/translate_static/css/ |
18 KB 4 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
main.js
translate.googleapis.com/translate_static/js/element/ |
3 KB 2 KB |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H3-Q050 |
element_main.js
translate.googleapis.com/element/TE_20200506_00/e/js/element/ |
238 KB 86 KB |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
1
www.freevisitorcounters.com/en/counter/render/741796/t/ |
2 KB 2 KB |
Image
image/png |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
202475292012346
form.jotform.com/ Frame FF9A |
0 0 |
Document
text/html |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
translate_24dp.png
www.gstatic.com/images/branding/product/1x/ |
825 B 951 B |
Image
image/png |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
googlelogo_color_42x16dp.png
www.gstatic.com/images/branding/googlelogo/1x/ |
910 B 998 B |
Image
image/png |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
translate_24dp.png
www.gstatic.com/images/branding/product/2x/ |
2 KB 2 KB |
Image
image/png |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H3-Q050 |
l
translate.googleapis.com/translate_a/ Frame EC28 |
3 KB 1 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Verdicts & Comments Add Verdict or Comment
18 JavaScript Global Variables
These are the non-standard "global" variables defined on the window object. These can be helpful in identifying possible client-side frameworks and code.
object| trustedTypes function| googleTranslateElementInit object| google function| trimTrailingSlash string| ctrHref string| ctrHref2 function| eInDoc function| lCheck boolean| linkfound object| ifr undefined| get undefined| src function| handleIFrameMessage object| closure_lm_768544 object| iframe object| els object| el string| linktext0 Cookies
Cookies are little pieces of information stored in the browser of a user. Whenever a user visits the site again, he will also send his cookie values, thus allowing the website to re-identify him even if he changed locations. This is how permanent logins work.
Indicators
This is a term in the security industry to describe indicators such as IPs, Domains, Hashes, etc. This does not imply that any of these indicate malicious activity.
coviduvlamp.com
form.jotform.com
translate.google.com
translate.googleapis.com
www.freevisitorcounters.com
www.gstatic.com
192.185.23.100
2606:4700:3032::681b:b58d
2a00:1450:4001:801::2003
2a00:1450:4001:803::200e
2a00:1450:4001:81f::200a
35.201.118.58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